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Abstract 
 
Transport of therapeutics across mucosal barriers provides an attractive route for non-
invasive drug delivery, if sufficient drug permeability can be achieved. In inflammatory 
conditions of the epithelial mucosa, the barrier characteristics were observed to be modified 
with the permeability of noxious molecules increased significantly due to, at least in part, 
elevated levels of proinflammatory cytokines leading to tight junction disruption. This work 
aims to investigate the effect of selected cytokines on the barrier characteristics of airway and 
intestinal cell cultures in vitro in order to improve the understanding of transport features 
across inflamed epithelial cell layers. Data indicated that a three-four days short-term 
treatment with tumor necrosis factors-alpha (TNF-Į) produced a significant effect on Calu-3 
cell layers and some effect on Caco-2 cells, as shown by decreased transepithelial resistance 
(TEER values and increased permeability of model permeant (fluorescein isothiocyanate 
dextran with molecular weight of 10kDa, FD10). On the other hand, short-term treatments 
with proinflammatory cytokines interleukin-4 and interleukin-13 IL-4 and IL-13 did not show 
significant effects on the tested cell lines. Combined effect of cytokines was shown to cause a 
significant effect on Calu-3 apparent permeability coefficient (Papp) when the combination 
contains TNF-ĮZKLOH WKH3app across Caco-2 layers was observed to be influenced by IL-
4/IL-13 combination; the effect being reduced when TNF-Į was present. In the situation of 
long-term treatment (for the duration of cell culture), IL-4 and IL-13 did not produce a 
significant effect on TEER and Papp for both cell lines when incubated for 21 days. TNF-Į
however produced a significant effect on FD10 permeability across layers of both cell lines. 
Finally, the work examined the expression features of tight junction proteins (TJP2 and TJP3) 
and endocytosis pathway components (LAMP1, RAB4A, and RAB5A) in the cell layers 
following a prolonged exposure to the proinflammatory mediator TNF-Į Results 
ii 
 
demonstrated that expression of the tested TJ proteins was downregulated, though 
endocytosis related proteins did not show alteration in their expression. These results 
therefore indicated that the presence of proinflammatory cytokines could be involved in the 
improvement in the transport of macromolecules through epithelial mucosa by affecting a TJ 
opening.  
  
iii 
 
Acknowledgements 
 
In the name of Allah, the Most Gracious and the Most Merciful. All praises to Allah for the 
strengths and His blessing in completing this thesis. 
First of all, I would like to express my deepest gratefulness to my supervisor, Dr Snow 
Stolnik-Trenkic, for her supervision, outstanding guidance from the very early stage of this 
research and providing me with an excellent atmosphere for doing research. Above all and 
the most needed, she provided me unlimited encouragement and support. 
I gratefully acknowledge to my co-supervisor, Dr Driton Vllasaliu, for his advice, 
supervision, crucial contribution and patiently corrected my writing. His invaluable help of 
constructive comments and suggestions throughout the experimental and thesis works have 
contributed to the success of this research. 
I would like to express my appreciation Dr Franco Falcone for his support and knowledge 
regarding gene expression work. In addition, I wish to extend my appreciation to Dr Ian 
Sayers for his help in the analysis of microarray gene expression data. Not forget, great 
DSSUHFLDWLRQJRWRWKHUHVWRI6QRZ¶VJURXS members that help me from time to time during 
the lab work. 
I wish to express my deepest appreciation to my government in the Kingdom of Saudi 
Arabia, especially King Abdulaziz City for Science and Technology (KACST) for their 
financial support. 
My parents deserve special mention for their inseparable support and prayers. My Father, Ali, 
in the first place is the person who put the fundament my 
iv 
 
the joy of intellectual pursuit ever since I was a child. My Mother, Zinah, is the one who 
sincerely raised me with her caring and gently love. 
Finally, words fail to express my appreciation to my wife, Amani. She was always there 
cheering me up and stood by me through the good times and bad. 
 
 
 
 
 
 
 
 
 
 
 
  
v 
 
 
Table of Contents 
Abstract ................................................................................................................................. i 
Acknowledgements .............................................................................................................. iii 
List of Figures ...................................................................................................................... ix 
List of Tables ...................................................................................................................... xii 
List of Abbreviations.......................................................................................................... xiii 
Chapter 1: Introduction ......................................................................................................... 1 
1.1 Mucosal Drug Delivery ................................................................................................ 1 
1.1.1  Transport Pathways across Epithelial Mucosa....................................................... 1 
1.1.2 Mucosal Barriers ................................................................................................... 2 
1.1.3  The Role of Epithelial Membrane Proteins on the Regulation of Transport 
Processes ....................................................................................................................... 5 
1.2 Effect of Cytokines on Mucosal Barriers Characteristics in Airway and Intestinal 
Inflammatory Diseases ...................................................................................................... 6 
1.2.1 Proinflammatory Cytokines ................................................................................... 6 
1.2.2 Proinflammatory Cytokines and Inflamed Mucosa .............................................. 11 
1.3 Cell Culture Models of Epithelium............................................................................. 14 
1.3.1 Calu-3 Cell Line .................................................................................................. 15 
1.3.2 Caco-2 Cell Line ................................................................................................. 17 
1.4 Conclusion ................................................................................................................. 19 
1.5 Project Aims .............................................................................................................. 20 
1.6 References ................................................................................................................. 21 
Chapter 2: Materials and General Methods .......................................................................... 30 
2.1 Materials .................................................................................................................... 30 
2.1.1 Cells and Cell Culture Consumables .................................................................... 30 
2.1.2 Biological Agents ................................................................................................ 31 
2.1.3 Model Macromolecular Drug .............................................................................. 31 
2.1.4 PCR .................................................................................................................... 32 
2.2 Methods ..................................................................................................................... 32 
2.2.1 Cell Maintenance................................................................................................. 32 
2.2.2 Measurement of Transepithelial Electrical Resistance (TEER) ............................ 34 
vi 
 
2.2.3 Effect of Cytokines on Tight Junctions: Measurement of TEER .......................... 36 
2.2.4 Effect of Cytokines on Tight Junctions: Measurement of Permeability ................ 37 
2.2.5 Confocal Microscopy Imaging of Tight Junction Protein, Zonula Occludens (ZO-1)
 .................................................................................................................................... 38 
2.2.6 Collection of Gene Microarray Data from GEO ................................................... 39 
2.2.7 Statistical Analysis .............................................................................................. 40 
Chapter 3: Effect of Cytokines on Barrier Characteristics of Human Airway Epithelial Cell 
Layers (Calu-3) ................................................................................................................... 41 
3.1 Introduction ............................................................................................................... 41 
3.2 Methods ..................................................................................................................... 44 
3.2.1 Effect of Site-Specific Cytokine Addition on Epithelial Barrier ........................... 44 
3.2.2 Effect of Cytokines on Zonula Occludens-1 Protein............................................. 45 
3.3 Results ....................................................................................................................... 46 
3.3.1 Effect of Site-Specific Cytokine Application on Calu-3 Barrier for 3 days ........... 46 
3.3.2 Effect of Basolateral Cytokine Application on Cell Layer Barrier: a Comparison 
between Different Cytokines ........................................................................................ 55 
3.3.3 Effect of Combined Cytokine Application on Calu-3 Layer ................................. 60 
3.4 Discussion ................................................................................................................. 66 
3.5 Conclusion ................................................................................................................. 70 
3.6 References: ................................................................................................................ 71 
Chapter 4: Effect of Cytokines on Barrier Characteristics of Human Intestinal Epithelial Cell 
Layers (Caco-2) .................................................................................................................. 75 
4.1 Introduction ............................................................................................................... 75 
4.2 Methods ..................................................................................................................... 77 
4.2.1 Effect of Site-Specific Cytokine Addition on Epithelial Barrier ........................... 77 
4.3 Results ....................................................................................................................... 78 
4.3.1 Effect of Site-Specific Cytokine Application on Caco-2 Barrier .......................... 78 
4.3.2 Effect of Basolateral Cytokine Application on Cell Layer Barrier: a Comparison 
between Different Cytokines ........................................................................................ 87 
4.3.3 Effect of Combined Cytokine Application on Caco-2 Barrier .............................. 91 
4.4 Discussion ................................................................................................................. 94 
4.5 Conclusion ................................................................................................................. 99 
4.6 References ............................................................................................................... 100 
Chapter 5: Effect of Long-Term Cytokines Treatment on Barrier Characteristics of Human 
Airway and Intestinal Epithelial Cell Layers ..................................................................... 103 
vii 
 
5.1 Introduction ............................................................................................................. 103 
5.2 Methods ................................................................................................................... 105 
5.2.1 Effect of Cytokines on Calu-3 and Caco-2 TEER .............................................. 105 
5.2.2 Effect of Cytokines on Calu-3 and Caco-2 Permeability .................................... 106 
5.3 Results ..................................................................................................................... 106 
5.3.1 Effect of Long-Term Cytokines Application on Calu-3 and Caco-2 Barrier 
Properties ................................................................................................................... 106 
5.4 Discussion ............................................................................................................... 113 
5.5 Conclusion ............................................................................................................... 116 
5.6 References ............................................................................................................... 117 
Chapter 6: Effect of Cytokines on the Expression of Human Intestinal and Airway Epithelial 
Barrier Genes .................................................................................................................... 120 
6.1 Introduction ............................................................................................................. 120 
6.2 Methods ................................................................................................................... 125 
6.2.1 Cell Culture and Cytokine Treatment ................................................................ 125 
6.2.2 Primer Design for PCR ...................................................................................... 126 
6.2.3 PCR Analysis .................................................................................................... 127 
6.3 Results ..................................................................................................................... 128 
       6.3.1 Expression Analysis of Candidate Genes«««««««««««««««...133 
6.3.2 Effect of TNF-ĮRQWKH([SUHVVLRQRI&DFR-2 and Calu-3 Barrier Genes............ 131 
6.4 Discussion ............................................................................................................... 135 
6.5 Conclusion ............................................................................................................... 138 
6.6 References ............................................................................................................... 139 
Chapter 7: Summary and Future Work .............................................................................. 146 
7.1 Overall Summary ..................................................................................................... 146 
7.2 Future Work ............................................................................................................ 149 
Chapter 8: Appendices ...................................................................................................... 150 
8.1 The Effect of TNF-ĮRQ&DOX-3 Cell Layers at Concentrations of (10, 25, and 50ng/ml)
 ...................................................................................................................................... 150 
8.2 Affymetrix Array of Candidate Genes from (GeneCards)......................................... 151 
8.3 Normalizing Gene expression Data from (GEO) ...................................................... 163 
8.3.1 Study 1 .............................................................................................................. 163 
8.3.2 Study 2 .............................................................................................................. 165 
8.3.3 Study 3 .............................................................................................................. 167 
viii 
 
8.2.4 Study 4 .............................................................................................................. 171 
 
  
ix 
 
List of Figures 
 
Figure 1.1 Transport mechanisms across epithelial mucosa. .................................................. 2 
Figure 1.2 The tight junction complex composed of several proteins ..................................... 4 
Figure 1.3 Schematic representation of IL-4 and IL-13 receptors ...................................... 8 
Figure 1.4 Schematic representation of the mechanism of TNF-Į HIIHFW RQ WLJKW MXQFWLRQ
complex during inflammation reaction. ............................................................................... 10 
Figure 1.5  Schematic represent the structure of Calu-3 monolayers ................................. 16 
Figure 1.6 Schematic represent the structure of Caco-2 monolayers .................................... 18 
Figure 2.1 Schematic representation of the Voltohmmeter (EVOM, World Precision 
Instruments) system used to measure transepithelial electrical resistance. ............................ 35 
Figure 3.1 TEER measurements of Calu-3 cells cultured on filters using AIC conditions and 
treated by a) TNF-ĮQJPOEIL-4 (5ng/ml), c) IL-13 (5ng/ml) for 72 hours. ............... 49 
Figure 3.2 Effect of 96 hours cytokine treatment on FD10 permeability across Calu-3 layers 
DWÛ&([SRVXUHWRD TNF-ĮQJPOE,/-4 (5 ng/ml) and c) IL-13 (5 ng/ml). ........... 52 
Figure 3.3 Effect of 96 hours cytokine treatment on FD10 permeability across Calu-3 layers 
DWÛ&([SRVXUHWRD71)-ĮQJPOE,/-4 (5 ng/ml) and c) IL-13 (5 ng/ml). ............. 55 
Figure 3.4 TEER measurements of Calu-3 cells cultured on filters using AIC conditions and 
treated for 96 hours with cytokines (IL-4 and IL-13 at (5 ng/ml) and TNF-ĮDWQJPO . 56 
Figure 3.5 Effect of tested cytokines on FD10 permeability across Calu- OD\HUV DW Û&
Cytokines treatment for 96 hours. ........................................................................................ 57 
Figure 3.6 Effect of tested cytokines on FD10 permeability across Calu- OD\HUV DW Û&
Cytokines treatment for 96 hours. ........................................................................................ 58 
Figure 3.7 a) Immunostaining for ZO-1 tight junction protein in cell layers treated with TNF-
ĮIRUIRXUGD\V .................................................................................................................... 60 
x 
 
Figure 3.8 TEER measurements of Calu-3 cells cultured on filters using AIC conditions and 
treated by cytokines combinations (IL-4 and IL-13 at (5ng/ml) and TNF-ĮDWQJPO) for 4 
days. ................................................................................................................................... 62 
Figure 3.11 Immunostaning of TJs protein (ZO-1) of Calu-3 cells pre-treated with cytokines 
combinations for 4 days. ..................................................................................................... 65 
Figure 4.1 TEER measurements of Caco-2 cells cultured on filters treated by a) TNF-Į
(25ng/ml), b) IL-4 (5ng/ml), c) IL-13 (5ng/ml) for 96 hours. ............................................... 81 
Figure 4.2 Effect of a) TNF-Į QJPO E IL-4 (5ng/ml), c) IL-13 (5ng/ml) on FD10 
permeability across Caco-OD\HUVDWÛ& .......................................................................... 84 
Figure 4.3 Effect of a) TNF-Į QJPO E IL-4 (5ng/ml), c) IL-13 (5ng/ml) on FD10 
permeability across Caco-OD\HUVDWÛ& ............................................................................ 87 
Figure 4.4 TEER measurements of Caco-2 cells cultured on filters and treated by individual 
cytokines {IL-4 and IL-13 at (5ng/ml) and TNF-ĮDWQJPO`IRUGD\V ........................ 88 
Figure 4.5 Effect of individual cytokines on FD10 permeability across Caco-OD\HUVDWÛ&
 ........................................................................................................................................... 89 
Figure 4.6 Effect of individual cytokines on FD10 permeability across Caco-OD\HUVDWÛ&
 ........................................................................................................................................... 90 
Figure 4.7 TEER measurements of Caco-2 cells cultured on filters and treated by combined 
cytokines {IL-4 and IL-13 at (5ng/ml) and TNF-ĮDWQJPO`IRUGD\V ....................... 92 
Figure 4.8 Effect of combined cytokines on FD10 permeability across Caco-OD\HUVDWÛ&
 ........................................................................................................................................... 93 
Figure 4.9 Effect of combined cytokines on FD10 permeability across Caco-OD\HUVDWÛ&
 ........................................................................................................................................... 94 
Figure 5.1 TEER profiles of a) Calu-3 and b) Caco-2 cells cultured on Transwell® filters and 
treated for 21 days with IL-4, IL-13 (5ng/ml) and TNF-ĮQJPO ................................. 108 
xi 
 
Figure 5.2  Effect of long-term cytokines treatment on FD10 permeability across a) Calu-3 
and b) Caco-2 monolayers ................................................................................................. 110 
Figure 5.3  Comparison of the effect of long-term and short-term TNF-Į QJPO
treatment on FD10 permeability across a) Calu-3 and b) Caco-2 monolayers. ................... 112 
Figure 6.1 Graph shows significant difference between the expression of normal control 
(healthy individuals) and diseased condition (asthmatic patients) in TJP2 gene. ................ 129 
Figure 6.2 Graph shows significant difference between the expression of normal control 
(healthy individuals) and diseased condition (asthmatic patients) in TJP3 gene. ................ 130 
Figure 6.3 Graph shows significant difference between the expression of normal control 
(healthy individuals) and diseased condition (asthmatic patients) in LAMP1 gene. ............ 130 
Figure 6.4 Graph shows significant difference between the expression of normal control 
(healthy individuals) and diseased condition (asthmatic patients) in RAB4A gene. ............ 130 
Figure 6.5 Graph shows significant difference between the expression of normal control 
(healthy individuals) and diseased condition (asthmatic patients) in RAB5A gene. ............ 131 
Figure 6.6 Effect of time-dependent proinflammatory cytokine TNF-ĮQJPO treatment on 
mRNA expression of Caco-2 and Calu-3 epithelial membrane genes. ................................ 134 
Figure 8.1 Effect of 10, 25, and 50ng/ml of TNF-ĮRQ7((5RI&DOX-3 layer. ................... 150 
 
 
 
  
xii 
 
List of Tables 
 
Table 2.1 Summary of four studies examined from GEO database....................................... 40 
Table 6.1 Several genes whose expression features could play key roles in remodelling of the 
epithelium in inflammatory conditions. ............................................................................. 123 
Table 6.2 List of forward and reverse primers that used to examine the expression features of 
candidate genes ................................................................................................................. 126 
Table 6.3. Summary of gene expression data analysis result for a list of candidate genes 
examined by GEO database ............................................................................................... 126 
 
 
 
 
 
 
 
xiii 
 
List of Abbreviations 
 
%                         Percentage 
°                           Degree 
°C                        Degree Celsius 
Å                         Angstrom  
AB/AM              Antibiotic/Antimycotic 
AHR                   Airway Hyper Reactivity 
AIC                    Air-Interfaced Culture 
ATCC                American Type Culture Collection 
bp                       Base Pair 
BSA                   Bovine Serum Albumin 
cDNA                Complementary Deoxyribonucleic Acid 
CAV1                Caveolin 1 protein 
CDH1                E-cadherin 
CLTC                Clathrin Heavy Chain 
CLDN                Claudin  
cm2                              Square Centimetre  
CO2                   Carbon dioxide 
CUBN               Intrinsic Factor-cobalamin Receptor 
xiv 
 
Da                     Dalton 
DABCO           1,4-Diazabicyclo-octane 
DNA                     Deoxyribonucleic Acid 
DMEM             'XOEHFR¶V0RGLILHG(DJOHV0HGLXP 
DMSO              Dimethylsulphoxide 
ECACC            European Collection of Cell Cultures 
EDTA              Ethylene Diamine Tetraacetic Acid 
EEA1              Early Endosome Antigen 1 
EMEM             (VVHQWLDO0LQLPXP(DJOH¶V0HGLXP 
EVOM             Epithelial Voltohmmeter 
FBS                 Foetal Bovine Serum 
FCGRT           Fc Fragment of IgG Receptor Transporter Alpha 
FD10               Fluorescein Isothiocyanate-dextran 10 kilodalton 
FDA                Food and Drug Administration 
FITC               Fluorescein Isothiocyanate 
FPR1              Formyl Peptide Receptor 1  
FOLR1           Folate Receptor 1  
GAPDH         Glyceraldehyde 3-phosphate dehydrogenase 
GEO               Gene Expression Omnibus 
xv 
 
GI                 Gastro Intestinal 
HBSS           +DQN¶V%DODQFHG6DOW6ROXWLRQ 
HEPES         4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IBD              Irritable Bowel Disease 
IL-4              Interleukin-4 
IL-5Į      Interleukin-4 Receptor Alpha 
 IL-13           Interleukin-13 
IL-5Į   Interleukin-13 Receptor Alpha 
JAM             Junctional Adhesion Molecules 
kDa              Kilodalton 
LCC             Liquid-covered Culture 
M6PR          Mannose-6-phosphate Receptor 
M                 Molar 
mM              Millimoles 
ml                Millilitre 
MLCK         Myosin Light-chain Kinase  
mRNA          Messenger Ribonucleic acid 
MW             Molecular weight 
NCBI           National Centre for Biotechnology Information 
NF-kB         Nuclear Factor Kappa B 
xvi 
 
nm               Nanometer 
LAMP1       Lysosomal-associated Membrane Protein 1 
OCLN         Occludin 
Papp              Apparent permeability coefficient 
PCR            Polymerase Chain Reaction 
PBS            Phosphate Buffered Saline 
RAB           RAS Oncogene Family 
SD              Standard deviation  
TBE            Tris-Borate-EDTA 
TEER         Transepithelial Electrical Resistance 
Th-cell       T Helper Cell 
TJ              Tight Junction 
TJP            Tight Junction Protein 
TNF-Į  Tumor Necrosis Factor-alpha 
v/v             Volume per unit Volume 
w/v            Weight per unit Volume 
ZO-1          Zonula occludens-1 
ȝO             Microlitre 
ȝP              Micrometer 
ȍ            Ohm (electrical resistance unit)
Chapter 1                                                                                                                                    Introduction                                    
 
1 
 
Chapter 1 
 Introduction 
 
 
1.1.1 Mucosal Drug Delivery 
 
In the field of drug delivery, mucosal delivery is considered a very attractive option for the 
administration of therapeutic drugs [1]. Currently, considerable effort in pharmaceutical 
research is focusing on the epithelial drug transport mechanisms involved in mucosal drug 
delivery [1]. One of the main advantages of mucosal delivery is patients` compliance when 
using non-invasive methods [2]. Furthermore, mucosally-delivered therapeutics have the 
capacity to escape the hepatic first-pass mechanism [2]. The mucosal epithelia considered for 
drug delivery includes several routes: oral, buccal, pulmonary, vaginal, nasal and ocular [1]. 
 
1.1.2 Transport Pathways across Epithelial Mucosa 
 
Macromolecules and nanoparticles have been shown to be transported across epithelial 
mucosa using different mechanisms [3]. The paracellular pathway is one of the major 
potential mechanisms of transmucosal transport, particularly for hydrophilic and relatively 
smaller macromolecules [4]. In this route, hydrophilic macromolecules and, according to 
some authors, nanoparticles pass through restrictive complexes between adjacent cells called 
tight junctions [4][5]. Hydrophobic and bigger macromolecules, and nanoparticles can be 
also able to cross the mucosal cell layer through a transcellular pathway [6]. Transcellular 
transport may occur by  transcytosis (carrier-mediated mechanism) [4][7]. In this pathway, 
the material binds to specific receptors and is captured in vesicles that move the 
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macromolecules from the apical to the basolateral side [7][8]. Figure 1.1 shows a summary of 
the potential transport pathways. 
 
 
Figure 1.1  Transport mechanisms across epithelial mucosa.  
A) Paracellular pathway (red). B) Transcellular pathway (green). C) Transcytosis pathway 
(carrier-mediated) (blue). 
 
1.1.2  Mucosal Barriers 
 
Understanding the physiology of mucosal tissue is important in the field of drug delivery, 
because it may lead to improvements in the absorption properties of new therapeutic agents. 
To achieve delivery, different barriers that mucosa present need to overcome successfully. In 
the following sections, some of these barriers will be described in more detail. 
 
 
 
Chapter 1                                                                                                                                    Introduction                                    
 
3 
 
1.1.2.1  Tight Junctions Barrier 
 
Typically cells in mucosal tissue are connected apically by a strong paracellular complex of 
proteins, known as tight junctions (TJ). This makes the mucosal barrier very restrictive 
against the free diffusion of solutes [9][10]. Moreover, the transport selectivity of water, 
substances and ions could be controlled by the tight junction complex [9]. Several protein 
components have been reported to play a key role in tight junction function and structure 
[11], as shown in figure 1.2. Tight junction proteins (zonula occludens - ZO-1, ZO-2, ZO-3), 
trans membrane proteins (claudins, occludin) and the junctional adhesion molecule (JAM) 
have been documented to contribute to the TJ structure [9].  
 
It has been suggested that the molecules with molecular weights of more than 3.5 kDa  would 
not be able to cross the paracellular route in healthy barriers because the space width of a TJ 
is about 15 Å [12][13]. When the tight junction function has been disrupted, the free diffusion 
of noxious substances would be increased, and several diseases could be significantly 
stimulated [10]. It has been shown in a number of  inflammation studies that intestinal and 
respiratory inflammatory conditions are essentially associated with defectiveness in tight 
junctions [14][15][16]. This observation will be described later in this chapter. 
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Figure 1.2  The tight junction complex composed of several proteins such as claudins, 
RFFOXGLQ DQG MXQFWLRQDO DGKHVLRQ PROHFXOH -$0 ZKLFK µVHDO¶ WKH LQWHUFHOOXODU VSDFH
tightly.  
 
 
1.1.2.2  Mucus Barrier 
 
The mucus barrier that covers most epithelial membranes plays an important physiological 
function in vivo [17][18]. It is secreted by mucosal gland or goblet cells [7]. Intestinal and 
respiratory tissues, for example, are known to secrete mucus to protect their mucosa from the 
free diffusion of harmful agents from the external environment [19][12]. Moreover, other 
functions have been observed with mucus in the human body, such as lubrication [20], anti-
microbial effects, and water balance [21]. Drug absorption was also documented to be 
affected by the mucus layers [21]. 
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Mucus constituents are usually dependent on the tissue type, but it is generally composed of 
water, glycoproteins and lipids, in addition to other components present in low amounts, such 
as minerals [21]. One of the most common components of mucus is mucin. This 
macromolecular compound forms a very viscous layer on epithelium, which has a profound 
effect on the transport of molecules [21][22]. The transport of molecules across the mucus 
layer depends on several factors, such as the molecular size and affinity for mucus 
components [21]. It must be noted that a good understanding of mucus production in normal 
and diseased tissues would improve drug delivery efficiency across mucosa [21]. The 
alteration in mucus properties has been reported in different disease conditions, including 
mucus over-secretion or changes in mucus viscosity or thickness [23][24].  
 
1.1.3 The Role of Epithelial Membrane Proteins on the Regulation of Transport 
Processes 
 
A number of investigations have demonstrated that several membrane proteins play an 
essential function in the regulation of transport processes across mucosal membranes in 
humans. TJP2 and TJP3 proteins were reported to be significantly involved in the 
permeability of substances across intercellular route [25][26][27]. Furthermore, several other 
proteins were suggested to contribute in the regulation of transport processes involved in the 
transcytosis pathway. These include, for example, RAB4A, RAB5A and LAMP1 
[28][29][30]. 
TJP2 (ZO-2) and TJP3 (ZO-3) are major components of the tight junction complex regulation 
and formation which controls the transport across paracellular route of epithelial monolayers 
[31][5][32]. In healthy epithelial tissue, TJP2 and TJP3 contribute to the prevention of the 
transport of noxious elements across epithelium into the systemic circulation, while in 
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inflamed tissue the tight junctions were reported to be damaged in inflamed tissue and 
characterised by an increased permeability of substances using the paracellular route [33].  
RAB4A has been documented to regulate  the endocytosis pathway of transport and cell-cell 
adhesions of epithelial cells [29][34]. Moreover, RAB5A and LAMP1 contribute in early and 
late endosomal process, respectively [30][35]. A study reported that LAMP1 plays multiple 
functions in transport across cells via endocytosis [36]. RAB4A and RAB5A are important 
members of the RAB family and have a role in the regulation of early and recycling 
endosomes processes, respectively, and also the endocytosis pathway of transport in a wide 
range of cells [34][37][38][39].  
It might be worth examining the expression features of these proteins in normal and 
inflammatory conditions in order to establish an understanding of their involvement in 
transport process regulation. Also, a study on the expression of these proteins will determine 
whether the inflammation reaction influences the transport across the mucosal tissue by 
remodelling the tight junction complex (the paracellular route) or by affecting the transcytosis 
mechanism. 
 
 
1.2  Effect of Cytokines on Mucosal Barriers Characteristics in Airway and Intestinal 
Inflammatory Diseases 
 
1.2.1  Proinflammatory Cytokines 
 
Cytokines are relatively small endogenous proteins with low molecular weights between 8 
and 40 kDa [40], which are mainly released by immune cells [41]. In terms of the site of 
production, cytokines can be categorised into two groups: (i) T-helper 1 cytokines, such as 
TNF-Į DQG  LL 7-helper 2 cytokines, such as IL-4 and IL-13 [42]. Cytokines play an 
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essential physiological function in the human body by providing a connection between the 
immune system and the (inflamed) tissues [43] in order to stimulate a host defence 
mechanism [40][44]. One study, for instance, demonstrated that the human immune system 
can be induced by cytokines during inflammation reactions [42]. 
  
Nowadays, numerous laboratories use cytokines to examine the immune reactions of human 
mucosa in vitro [42]. Moreover, proinflammatory cytokines have been shown to have a 
significant effect on the structure and function of epithelial cell layers of in vitro models [18]. 
An experimental in vitro study on epithelial models has, for example, demonstrated that 
proinflammatory cytokines play a key role in tight junction dysfunction [18]. Recent research 
stated that a wide array of proinflammatory cytokines play a role in tight junction 
remodelling through the disruption of occludin and claudin regulation [45][46][10]. The 
regulation of tight junction proteins by proinflammatory cytokines is believed to be one of the 
major mechanisms behind the development of inflammatory disorders [45]. At present, 
several cytokine antagonist agents are under clinical investigation due to the possible benefit 
of using these agents when treating inflammatory disorders of airways and the intestines 
[18][47]. In the experimental chapters in this thesis, three proinflammatory cytokines, IL-4, 
IL-13, and TNF-Į ZHUH XVHG WR LQYHVWLJDWH WKHLU HIIHFW RQ WKH EDUULHU FKDUDFWHULVWLFV RI
airway and intestinal epithelia.  
 
1.2.1.1  Interleukin 4 and 13 (IL-4 and IL-13) 
 
The proinflammatory cytokines that were selected for use in this project are interleukin 4 and 
13. Interleukins are a group of cytokines that include several cytokines, such as IL-4 and IL-
13, which play a significant function in the regulation of the epithelial paracellular pathway 
[45]. Both IL-4 and IL-13 are released endogenously from T-helper 2 cells [18]. An inflamed 
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epithelial membrane can be considered as one of the main sources of these interleukins in 
such inflammation reactions [18][16]. It has been reported that both IL-4 and IL-13 play an 
essential role in increasing the permeability of mucosa during inflammatory disorders [48]. 
With regard to the effect of combined cytokines, synergetic influence has been reported with 
IL-4 and IL-13 when combined with TNF-Į[49]. 
 
Figure 1.3 illustrates that IL-4 and IL-13 share the receptors; therefore, numerous 
investigations have stated that these interleukins furthermore share a similar physiological 
function [48]. Both IL-4 and IL-13 have the ability to bind the IL-5Į,/-5ĮFRPSOH[
which then activates the inflammation response in several diseases [50]. 
 
 
Figure 1.3 Schematic representation of IL-4 and IL-13 receptors to show that these 
interleukins share the same receptors (IL-5Į,/-5Į[50]. 
 
 
IL-4 and IL-13 have been shown to play important functions in the development of asthma 
[51] and some intestinal disorders [52]. Several studies have documented that the treatment of 
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respiratory and intestinal epithelium with IL-4 could increase the permeability of the cell 
layer [45]. IL-4 appears to induce paracellular permeability via the downregulation of tight 
junction proteins, particularly ZO-1 and occludin [45]. A similar effect has been observed 
with IL-13, showing an increase in the permeability of the paracellular route and down 
regulation of tight junction proteins [45]. IL-4 and IL-13 play a significant role in the 
progression of intestinal [52] and pulmonary inflammation reactions [53] by remodelling the 
tight junction complex structure and function [52]. Interestingly, both IL-4 and IL-13 have 
dual inflammatory properties by showing anti-inflammatory effects in some cases and 
proinflammatory actions in other conditions [40].  
 
1.2.1.2  Tumour Necrosis Factor-alpha (TNF-Į 
 
The further important proinflammatory cytokine that the project will focus on is TNF-Į
TNF-Į LV D ORZ PROHFXODU ZHLJKW F\WRNLQH WKDW LV UHOHDVHG E\ 7K-1 cells [54]. Several 
cytokines that are released in inflammation reactions have been shown to be induced initially 
by TNF-Į [55]. TNF-ĮKDV EHHQ UHSRUWHGWREH LQYROYHG LQ VRPH LQWHVWLQDO DQG UHVSLUDWRU\
inflammatory disorders by causing the dysfunction of tight junctions [45]. The mechanism of 
TNF-Į LQIOXHQFHRQ WLJKW MXQFWLRQV PLJKWEHYLD LQGXFLQJ QXFOHDU IDFWRUNDSSD% 1)-kB), 
which activates the expression of myosin light chain kinase protein (MLCK). This protein, in 
turn, plays a role in the down regulation of ZO-1 protein [45][56], as shown in figure 1.4. 
Moreover, treatment of the epithelial cell layers with TNF-ĮPLJKWSURYLGHDOWHUDWLRQVLQWKH
function and structure of tight junctions function and structure, and therefore change the 
permeability properties of the membrane [45]. Most of the effect of TNF-ĮHIIHFWKDVEHHQ
seen when combined with other cytokines [57]. 
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Figure 1.4 Schematic representation of the mechanism of TNF-ĮHIIHFWRQWLJKWMXQFWLRQ
complex during inflammation reaction. 
 
 
A biopsy from an asthmatic individual demonstrated an increased TNF-ĮOHYHODQGVXJJHVWHG
that the use of anti-TNF-ĮFRXOGGHFUHDVH WKH VHYHULW\RI DVWKPD >@7KH OHYHORI71)-Į
mRNA was shown to be expressed in asthma [32][15], leading to increased mucus 
generation, AHR and other features of asthma [33].  
 
A number of strategies have been recommended to control asthma, such as antagonising the 
effect of multifunctional cytokines, for instance blocking the TNF-Į UHFHSWRU
[10][19][58][23]. A recent investigation documented that the treatment of asthmatic patients 
with anti-TNF-Į LPSURYHG WKH DFXWH DQG FKURQLF V\PSWRPV VLJQLILFDQWO\ >@ ,Q DGGLWLRQ
one of the possible therapeutic approaches that could help in asthma management is to protect 
the tight junction complex from the disruptive effects of cytokines [10].  
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1.2.2  Proinflammatory Cytokines and Inflamed Mucosa 
 
A number of research publications have reported that the main component of the paracellular 
pathway, the tight junction complex, can be controlled by cytokines [54]. In several intestinal 
and respiratory inflammatory disorders, cytokines have been shown to play an important 
function in remodelling the tight junction complex, and therefore increasing the permeability 
of noxious substances through the paracellular space [45]. Alterations in the structure and 
function of tight junctions structure and function could increase the risk of such inflammatory 
diseases [54]. It should be noted that inflammation reactions could be induced by the 
downregulation of anti-inflammatory cytokines or by an increase in the release of pro-
inflammatory cytokines [48].  
 
Proinflammatory cytokines could increase the permeability of harmful agents through 
intercellular pathways by disruption of the tight junction complex, and this might be one of 
the contributing factors  to several inflammatory disorders, such as asthma and inflammatory 
bowel disease (IBD) [45][59]. The inflamed airway and intestinal cells in asthma and IBD, 
respectively, have been observed to be damaged due to the significant effect of 
proinflammatory cytokines [60][61][15]. Recently, increased paracellular permeability and 
decreased TEER have been shown for treatment of in vitro models of epithelium with such 
cytokines, which suggested the significant effect of pro-inflammatory agents on epithelial 
layer integrity [48]. Cytokines promote dysfunction of the tight junction barrier by 
disregulating the ZO proteins [54]. Two of the most common respiratory and intestinal 
diseases that are significantly stimulated by pro-inflammatory cytokines are asthma and IBD, 
which will be discussed in the following sections. 
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1.2.2.1  The Contribution of Pro-inflammatory Cytokines to Inflamed Airway 
Mucosa 
 
Asthma is a broad term that covers chronic inflammation reactions in the airway epithelium, 
characterised by various signs such as Airway Hyper Reactivity (AHR), increased mucus 
secretion and reversible bronchoconstriction [34]. By improving our understanding of 
inflammatory diseases of the lung, such as asthma, recent efforts have shifted the focus 
towards studying the biology and physiology of the epithelium [62]. Remodelling of the 
respiratory epithelium is one of the crucial characteristic features of asthma [63]. Alterations 
in the structure of the epithelium in such inflammatory processes may, in turn, cause 
increased mucus secretion by relevant components of the mucosa (goblet cells), dysfunction 
of epithelial tight junctions and fibrosis [63].  
Recent evidence points to an impaired barrier functionality of the epithelium in asthmatic 
patients, which results in increased permeability to exogenous substances and stimulation of 
inflammation processes in the lung [62]. Obtaining a full understanding of the pathological 
mechanisms involved in the regulation of the epithelial barrier is an essential prerequisite for 
the development of effective therapeutic agents to treat asthma [62]. 
A significant development in the pathophysiology of asthma in recent years has been the 
understanding of the involvement of cytokines in the disease [64][57]. Inflammatory and 
immunological cells have been documented to be the main sites of pro-inflammatory 
cytokine production in airway inflammation reactions [47]. Derived from Th-2 lymphocytes, 
cytokines mediate the inflammatory response in asthma [65] and are involved in the 
structural alterations in the airway epithelium of asthmatic patients [66], as well as in the 
activation of goblet cells, demonstrated by increased mucus production in asthma [67][65]. 
Recent studies have reported that cytokines play a key role in the regulation of tight junction 
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function in epithelial cells [54]. For example, work by Relova et al. [68] indicated that the 
disruptive airway barrier in asthma may occur due to the effect of pro-inflammatory 
cytokines.  
The actual mechanism of morphological and physiological modifications in inflamed airway 
epithelium by pro-inflammatory cytokines is still poorly understood [47]. The suggested 
mechanisms of airway remodelling are by (i) stimulating fibroblast cells, as shown with IL-4 
and IL-13, or by (ii) hyper secretion of mucus, as shown with TNF-Į >@ )XUWKHUPRUH
eosinophils have been reported to contribute fundamentally to the alteration of airway 
epithelium structures by the release of numerous proinflammatory cytokines [21][22].  
TNF-ĮDQGRWKHUSUR-inflammatory cytokines have been shown to be over-expressed in lung 
inflammatory diseases [69]. IL-4 was shown to be involved in the pathogenicity of asthma 
[70], while IL-13, which binds the alpha chain of the IL-4 receptor [70], could produce an 
even greater pro-inflammatory effect on airway epithelial cells in asthma than IL-4 [51]. 
Blocking IL-13 binding has shown a significant impact towards decreasing the severity of 
asthma [22]. To protect the respiratory tissue and suppress inflammation, cytokine inhibition 
may be a novel therapeutic target which could decrease the severity of asthma [71]. 
 
 1.2.2.2  Proinflammatory Cytokines Contribution to Inflamed Intestinal Mucosa 
 
Irritable bowel disease (IBD) covers several inflammatory disorders in the GI tract, such as 
Crohn`s and ulcerative colitis, which are mainly stimulated by cytokines [58]. The disruption 
of the intestinal tight junction barrier is one of the important features of Crohn`s disease 
[59][33]. Several inflammatory disorders have shown elevated levels of TNF-Į DQG
interleukins [8]. TNF-ĮSOD\VDVLJQLILFDQWUROHLQWKHG\VIXQFWLRQRIWKHLQWHVWLQDOHSLWKHOLDO
barrier, which actually presents a major mechanism behind the development of intestinal 
inflammatory diseases [8][17]. Furthermore, TNF-ĮZDVUHSRUWHGWRDFWDVVWLPXODWRURIRWKHU
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proinflammatory cytokines in intestinal inflammatory diseases, including IL-4 and IL-13 
[59].  
Numerous studies have documented that the intestinal tight junction complex is mainly 
regulated by the myosin light-chain kinase (MLCK) protein [52][59]. Upregulation of MLCK 
protein expression, which is associated with TNF-Į WUHDWPHQW ZDV UHSRUWHG LQ WKH in vitro 
model of intestinal epithelium [59][56]. Figure 1.4 shows the mechanism of TNF-Į
involvement in tight junction complex disruption. 
The mucus barrier in the intestine plays an important function in protecting the body from the 
external environment [8]. In Crohn`s disease, the intestinal mucus layer has been reported in 
several clinical investigations to be thicker than normal condition as a main feature of 
intestinal inflammation in several clinical investigations [8]. The proinflammatory cytokines 
have been found to play central roles in inducing mucus production and increasing the 
thickness of the mucus layer in intestinal inflammatory disorders [8].  
 
1.1.4 Cell Culture Models of Epithelium 
 
Epithelial cell layer is a biophysical barrier which provides a formidable obstacle to the entry 
of noxious materials into the body [72]. Pharmaceutical laboratories  have made considerable 
efforts to establish a well-characterised in vitro model of epithelium in order to (i) examine 
the cell barrier characteristics, (ii) investigate the drug transport properties in normal and 
diseased tissue [72][73], and (iii) predict the in vivo absorption of new therapeutic molecules 
[74]. Using primary cells in in vitro models would be ideal, but associated difficulties have 
been reported with primary models such as short lifespan [75] and the high cost of such cell 
cultures [72]. 
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Nowadays, established and validated in vitro models of epithelial cell lines are a common 
strategy in drug development to evaluate the mechanism of the transport of molecules across 
the membrane of target epithelium [76][74], and also to examine other important aspects of 
drug delivery. The majority of research laboratories currently use cell culture models based 
on established cell lines, due to various advantages, such as cost effectiveness, high 
reproducibility, a decrease in the use of animal models and the ease of use and maintenance 
[74][73]. 
 
In this project, cell line models of lung and intestinal epithelium were used to examine the 
effect of proinflammatory cytokines on the barrier characteristics of epithelial cell layers. 
These cell lines are Calu-3 and Caco-2, which will described in more details in the following 
sections. 
 
1.3.1  Calu-3 Cell Line 
 
Calu-3 is a well-characterised epithelial cell line, which originated primarily from a bronchial 
carcinoma of a sub-mucosal gland in a 25 year old Caucasian, and forms confluent 
monolayers in culture [72][77][78][79][80]. This cell line is widely used in numerous 
respiratory research studies to represent an in vitro model of airway mucosa [81][82]. 
Currently, Calu-3 is WKHµVWDQGDUG¶OD\HUIRUPLQJFHOOOLQHIRUOXQJUHVHDUFKLQSKDUPDFHXWLFDO
laboratories [83] and has been employed in several different applications, such as drug 
transport, metabolic property studies and epithelial barrier characteristics of airways 
[83][84][85].   
A number of other of cell lines were examined as in vitro models of lung epithelium. 
However most of these are either difficult to maintain, such as the NHBE cell line [86], 
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unable to form restrictive tight junctions and failed to provide appropriate TEER values, such 
as A549 [85], or failed to produce a phenotype similar to the relevant tissue [72]. There are 
several advantages when using Calu-3 cells in studies as a model of lung epithelium in vitro. 
Calu-3 has the ability to produce mucus and tight junction complexes with appropriate TEER 
values [87] that closely mimic the in vivo situation [75][83]. Moreover, the protein 
components of tight junction structures, such as Zonula occludens proteins and the adherin 
protein E-cadherin, were shown to be expressed in the Calu-3 cell line [75][85]. The 
formation of tight junction structures has mainly been assessed by TEER measurements [80].  
The Calu-3 cell line has been reported to form ciliated columnar cells, mimicking the in vivo 
epithelium phenotype of the upper airway tract lining, as shown in figure 1.5 [72]. 
 
 
Figure 1.5  Schematic represent the structure of Calu-3 monolayers (ciliated columnar 
cells, mucus and tight junctions). 
 
One of the key factors that influence epithelial cells culture in general, and Calu-3 in 
particular, is the culture system [80]. Calu-3 cells are usually cultured using two conditions: 
(i) liquid-liquid culture (LLC), where the culture medium covers both the apical and 
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basolateral cell sides, and (ii) air-interface culture (AIC), where the culture medium is present 
only on the basolateral side [72]. AIC culture creates conditions where cells demonstrate 
more cilia formation and mucus covering the cell surface [72][76]. Furthermore, the apical 
side of AIC cultures cells is exposed to air that mimics the in vivo conditions of the airway 
mucosa [79]. Also, TEER measurements in AIC were shown to correlate better to the in vivo 
FRQGLWLRQV WKDQ //& VKRZLQJ SK\VLRORJLFDO YDOXHV RI a ȍFP2 [83]. Microscopic 
investigations moreover confirmed that in the AIC system cellular appearance approximates 
the in vivo conditions more than in LLC [83].   
It must be noted that numerous factors could affect the quality of Calu-3 culture, such as the 
culture medium components and the number of passages [72]. Moreover, the number of cells 
seeded per cm2 of Transwell® filters also influences the time needed by cells to reach 
confluence; the usual seeding density used with Calu-3 is 100.000 cells/cm2 [86][80]. With 
such a seeding density, Calu-3 cells cultured on Transwell® filters will typically form 
polarised confluent monolayers within approximately 14 days of culture [80]. As has been 
shown in numerous studies, the relationship between the TEER value and the apparent 
permeability coefficient is inversely proportional [85][88]. This observation is due to the 
restrictiveness on tight junction that control the transport of molecules across epithelial 
membrane [88].  
 
1.3.2  Caco-2 Cell Line 
 
Caco-2 is a well-characterised epithelial cell line that was originally isolated from a human 
colo-rectal adenocarcinoma, which is used widely in intestinal research [89][17][90][74]. The 
Caco-2 cell line is the most commonly used tool for predicting drug transport across the 
intestinal system [89][6]. Caco-2 cells cultures have been shown to produce realistic TEER 
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values and have the ability to form confluent monolayers when cultured on Transwell® filters 
[48]. The inter-laboratory protocols and facilities have an essential influence on Caco-2 cells 
development [4][91]. Also, several further factors could have a significant impact on Caco-2 
cultures, such as medium components, the number of passages and the surface of the culture 
[4]. As illustrated in figure 1.6, Caco-2 cell line grown on Transwell support forms non-
ciliated simple columnar cells, which are phenotypically similar to the in vivo situation of the 
colon [17]. 
 
 
Figure 1.6  Schematic represent the structure of Caco-2 monolayers (simple columnar 
non-ciliated cells and tight junctions). 
 
 
TEER measurements confirmed that Caco-2 cells have the capacity to form restrictive 
intercellular tight junction complexes in vitro, ZLWK7((5YDOXHV!ȍFP2 [17][91][92]. 
Moreover, the tight junction proteins which play a key function in TJ formation were shown 
to be expressed in Caco-2 cell line [17][92]. When Caco-2 cells are cultured on Transwell® 
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filters with a seeding density of approximately 100.000 cells/cm2, cells will typically form 
confluent monolayers after 3 weeks [17]. Unlike the Calu-3 cell line, no mucus has been 
reported to be produced in Caco-2 cells [76]. Moreover, the paracellular space in Caco-2 cells 
has been found  to be larger than in Calu-3 cells [76]. A study documented that transport 
through the passive transcellular pathway substantially contributes to the transport of 
molecules across the Caco-2 cell layer , which mimics the in vivo system [19][6]. As shown 
in Calu-3 cell line, an inverse relationship was observed between TEER and the apparent 
permeability coefficient (Papp) in Caco-2 cells [19][6]. 
 
1.4  Conclusion 
 
In the area of drug delivery, studies on the further characterisation of epithelial cell barriers 
would be useful to expand the understanding of drug transport mechanisms across healthy 
and diseased (inflamed) mucosal tissue. It should be noted that inflammation reactions in 
lung and intestine mucosal tissues are mainly induced through structural and functional 
modification of the mucosal barrier (tight junctions and mucus layer), which are regulated by 
proinflammatory cytokines. Potential progress associated with this project might lead to an 
improved understanding of drug transport across epithelium in inflammatory respiratory and 
intestinal disorders. The epithelial cell layer in diseased conditions is found to be more 
permeable, relative to normal tissue. This could lead to increased transport across diseased 
tissue of biological or nanotechnology products, issues which are important for the 
pharmaceutical industry (drug delivery) and nanotoxicology research. To this end, the current 
project will assess the effects of proinflammatory cytokines of the permeability of epithelial 
cell lines in vitro. 
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1.5  Project Aims 
 
As mentioned in the introduction, the upregulation of pro-inflammatory cytokines is believed 
to be involved in the remodelling of mucosal tissue, and its barrier properties, during 
respiratory and intestinal inflammatory diseases. The aim of this project is to study the effects 
of selected pro-inflammatory cytokines on the barrier characteristics of in vitro models of 
intestinal and airway epithelium. For this purpose, Calu-3 and Caco-2 polarised monolayers 
will be employed to serve as in vitro models of airway and intestinal epithelium, respectively.  
The initial part of the project will focus on barrier characteristics of Calu-3 and Caco-2 cells 
with short-term cytokine treatments. After that, the work will examine the effects of long-
term treatment (exposure) of cytokines on these cell lines in order to compare them with 
short-term conditions. Thereafter, the work will explore the gene expression data available 
from published studies and make comparisons with experimental data obtained in the project.  
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Chapter 2 
Materials and General Methods 
 
 
2.1  Materials 
2.1.1  Cells and Cell Culture Consumables 
 
Calu-3 cells were purchased from the American Type Culture Collection (ATCC number; 
HTB-55) and used between passages 27-38. Calu-3 cells were routinely cultured in Eagle`s 
Minimum Essential Medium (EMEM). Caco-2 cells were purchased from the European 
Collection of Cell Cultures (ECACC number; 86010202) and used between passages 46-78. 
Caco- FHOOV ZHUH FXOWXUHG XVLQJ 'XOEHFFR¶V 0RGLILHG (DJOHV 0HGLXP '0(0 %RWK
EMEM and DMEM were purchased from Sigma-Aldrich (UK) and were supplemented with 
DQWLELRWLFDQWLP\FRWLF VROXWLRQ  8PO SHQLFLOOLQ  PJPO VWUHSWRP\FLQ  ȝJPO
amphotericin B), L-glutamine (200 mM), non-essential amino acids (100%), and foetal 
bovine serum (FBS, 10%). All media supplements were purchased from Sigma-Aldrich 
(UK). 
 
+DQN¶V %DODQFHG 6DOW 6ROXWLRQ +%66 VXSSOHPHQWHG ZLWK -(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) to maintain a pH of 7.4 was used as a drug transport 
medium; both of these materials were purchased from Sigma-Aldrich (UK), as was 
WU\SVLQ('7$ VROXWLRQ XVHG WR GHWDFK DGKHUHQW FHOOV LQ WKH SURFHVV RI FHOO µVSOLWWLQJ¶ RU
µSDVVDJLQJ¶3KRVSKDWHEXIIHUHGVDOLQH3%6WDEOHWVZHUHREWDLQHGIURP2[RLG8. 
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Polystyrene permeable inserts (Transwell®) for cell culture were supplied by Corning Life 
Sciences (USA). The Transwell® LQVHUWVZHUHRIPPGLDPHWHUDQGȝPSRUHVL]H&HOO
culture flasks (75 cm2, canted neck with vented caps), black 96-well plates, and sterile 
pipettes were all purchased from Corning Life Sciences (USA). Sterile centrifuge tubes were 
supplied by Grainer (USA). Cells were routinely counted (e.g. prior to seeding on multiwell 
plates) using an improved Neubauer haemocytometer, which was purchased from Scientific 
Laboratory Supplies (SLS, UK). 
 
2.1.2  Biological Agents 
 
Recombinant human cytokines, interleukin-4 (IL-4), interleukin-13 (IL-13) and tumour 
necrosis factor-alpha (TNF-ĮFDWDORJXHQXPEHUV-IL, 213-IL, and 210-TA, respectively) 
were purchased from R&D systems (UK). Mouse anti-human Zonula Occludens-1 (ZO-1; 
tight junction protein) antibody was obtained from Zymed (part of Invitrogen). FITC-labelled 
goat anti-mouse IgG was purchased from Sigma-Aldrich (UK). 
 
 
2.1.3  Model Macromolecular Drug 
 
Fluorescein isothiocyanate (FITC)-labelled dextran of approximately 10 kDa in molecular 
weight (FD10) was purchased from Sigma-Aldrich (UK). 
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2.1.4  PCR 
 
OneStep cDNA synthesis kit was purchased from Miltenyi Biotec (UK). JumpStart Taq DNA 
polymerase, 2% agarose gel, Tris-Borate-EDTA (TBE) buffer, ethidium bromide, and 
desalted primers were all purchased from Sigma-Aldrich (UK). SynGene Genius equipment 
and GeneSNAP software were used in this work for expression bands imaging. 
 
 
2.2  Methods 
2.2.1  Cell Maintenance 
2.2.1.1  Maintenance of Cells in Culture Flasks 
 
Calu-3 and Caco-2 cells were cultured in 75 cm2 flasks in standard cell culture conditions 
(37°C, 5% CO2 and 95% humidity) until confluence (point at which cells covered about 80-
95% of the surface of the flask). Cell growth was monitored regularly using an optical 
inverted microscope. Culture medium was changed every 2-3 days by aspirating the old 
medium and replacing with approximately 13 ml of fresh warm (37°C) medium. When 
confluent, cells were detached and a proportion of these transferred to a new flask. This 
SURFHVV RI FHOO µVSOLWWLQJ¶ RU µSDVVDJLQJ¶ ZDV FRQGXFWHG E\ UHPRYLQJ WKH FXOWXUH PHGLXP
washing adherent cells with approximately 5 ml of warmed (37°C) PBS to remove any 
residual medium and dead cells, followed by the addition of  approximately 3 ml of 2.5% 
trypsin/EDTA solution. Cells were incubated with trypsin/EDTA solution for ~15 min (Caco-
2 cells) and ~20 min (Calu-3 cells) until cells were separated from the flask surface. It was 
noted that Calu-3 cells are more adherent than Caco-2, therefore requiring longer incubation 
time with trypsin/EDTA solution. Thereafter, approximately 8 ml of culture medium was 
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added to the suspension of cells in trypsin/EDTA; this was done to inhibit the action of 
trypsin (which could be damaging to the cells if in contact with the cells for prolonged 
periods). The cell suspension was then transferred to a sterile 15 ml centrifuge tube and the 
cells were pelleted by centrifugation at 15,000 rpm for 5 min. The supernatant was discarded 
and fresh culture medium added to the pelleted cells to produce a cell suspension. 
Approximately 1/6-1/3 of the resulting cell suspension (i.e. resulting in cell splitting ratios of 
1:6 ± 1:3) was transferred to a new flask, which contained 12-13 ml of fresh culture medium 
(warmed to 37°C).  
 
2.2.1.2  Cell Seeding on Transwells® 
2.2.1.2.1  Calu-3 Cells 
 
Calu-3 cells were initially cultured in 75 cm2 flasks until confluence. Cells were then 
detached from the flask surface according to the method described in section 2.2.1.1 Cells (in 
the VXVSHQVLRQZHUHFRXQWHGXVLQJDKDHPRF\WRPHWHUIROORZHGE\µVHHGLQJ¶RQ7UDQVZHOO® 
filters. Cell seeding was conducted by transferring a volume of cell suspension containing 
100.000 cells into each Transwell® insert (1.1 cm2 filter area). The wells were filled with 
culture medium (EMEM), with the overall apical compartment volume of 0.5 ml and 
basolateral compartment volume of 1.5 ml. Following a 2-day culture period post-seeding in 
conditions where cells were covered by the culture medium on both apical and basolateral 
sides (i.e. liquid-FRYHUHGFXOWXUHµ/&&¶FHOOVZHUHWKHUHDIWHUH[SRVHGWRWKHFXOWXUHPHGLXP
(0.5 ml) only on their basolateral side. This condition where the cell layers are in contact with 
the culture medium on their basal side and not RQ WKH DSLFDO VLGH LV WHUPHG µDLU-interfaced 
FXOWXUH¶$,&7KHVHFRQGLWLRQVZHUHHPSOR\HGLQWKLVZRUNIRU&DOX-3 culture as it has been 
shown that the resulting cell cultures more closely resemble the airways in vivo compared to 
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liquid-covered culture (LCC). The culture medium (EMEM) was replaced regularly every 2-3 
days. Calu-3 cells were typically cultured on transwells for 3 weeks. Cell confluence and the 
integrity of the cell layer were confirmed by measurement of transepithelial electrical 
resistance (TEER), which will be described in section 2.2.2.  
  
2.2.1.2.2  Caco-2 Cells 
 
Caco-2 cells were cultured in 75 cm2 flasks until confluence. Cells were then detached from 
the flask surface (by addition of trypsin) according to the method described in section 2.2.1.1 
Cells were counted using a haemocytometer, followed by seeding on Transwell® filters at 
100.000 cells/well (1.1 cm2 filter area). 0.5 ml of the culture medium (DMEM) was added to 
the apical compartment and 1.5 ml to the basolateral compartment. Caco-2 cells were 
cultured using liquid-covered culture conditions, with the culture media present on both 
apical and basolateral sides of the cells. The culture medium was replaced regularly, every 2-
3 days. Caco-2 cells were typically cultured on transwells for 3 weeks. Cell confluence and 
the integrity of the cell monolayer were confirmed by measurement of TEER (next section). 
 
 
2.2.2  Measurement of Transepithelial Electrical Resistance (TEER) 
 
Measurement of transepithelial electrical resistance (TEER) is a technique typically 
employed in cell culture laboratories as an indication of epithelial cell growth, confluence and 
the intactness of the cell monolayer. TEER is also a measure of tight junction formation in 
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epithelial cells. Figure 2.1 depicts the system that is typically used in the laboratory to 
measure TEER. 
TEER was measured in the work using an EVOM (World Precision Instruments, USA) 
YROWRKPPHWHUHTXLSSHGZLWKDSDLURI µFKRSVWLFN¶HOHctrodes (Figure 2.1) measurements to 
detect monolayer confluence and cell integrity. The electrodes were initially sterilised (in 
ethanol), followed by washing in PBS. To obtain a reading, the chopstick electrodes were 
immersed in the culture medium bathing the cells, with the longer electrode immersed in the 
medium present on the basolateral chamber and the shorter electrode in the medium on the 
apical side. 
 
  
 
 
Figure 2.1  Schematic representation of the Voltohmmeter (EVOM, World Precision 
Instruments) system used to measure transepithelial electrical resistance. 
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With Calu-3 cells cultured under AIC, culture medium from the basal side was replaced by 
fresh culture medium, added to both apical and basolateral sides (0.5 ml and 1.5 ml, 
respectively). Cells were then incubated with the culture medium for approximately 30 min 
(in normal cell culture conditions), at which point TEER was measured following the 
SURFHGXUH GHVFULEHG DERYH 7KH 7((5 YDOXHV LQ WKLV WKHVLV DUH H[SUHVVHG DV ȍFP2) and 
background reVLVWDQFHGXHWRWKHILOWHUaȍFP2) was subtracted from the reported values. 
 
2.2.3  Effect of Cytokines on Tight Junctions: Measurement of TEER 
 
2QO\ LQWDFW SRODULVHG FHOO OD\HUV ZHUH LQFOXGHG LQ WKHVH H[SHULPHQWV 7KH µLQWDFWQHVV¶ ZDV
determined by measurement of TEER. Only cells expressing a TEER of > 300 and 1000 
ȍFP2 for Calu-3 and Caco-2 cell layers, respectively, were included in these experiments.  
Cytokines (IL-4; 5ng/ml), (IL-13; 5ng/ml) and (TNF-ĮQJPOZHUHDGGHGRQ WKHDSLFDO
side of confluent cell layers of Calu-3 and Caco-2, with fresh culture medium applied on the 
basal side of the cells. Cells were incubated with the cytokines for 3-4 days, with TEER 
measurements conducted every day.  
In another experimental set-up, the cells were treated with the cytokines for a longer duration. 
Here, cytokines (IL-4; 5ng/ml), (IL-13; 5ng/ml) and (TNF-ĮQJPOZHUHDSSOLHGDIWHU
days of culturing the cells in Transwell® Filters and cells were feeding by fresh medium 
containing the cytokines every 2 days during 21 days of study. TEER modifications are 
reported as a percentage of the baseline value (i.e. TEER value before cytokines addition, 
when time is zero). All experiments were conducted with n = 3-4. 
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2.2.4  Effect of Cytokines on Tight Junctions: Measurement of Permeability 
 
Permeability studies were conducted on polarised cell layers, previously incubated with 
cytokines (IL-4; 5ng/ml), (IL-13; 5ng/ml) and (TNF-Į QJPO IRU  GD\V &HOO OD\HU
integrity was confirmed by TEER measurements (detailed in the previous section). TEER 
was also measured after the permeability experiment to ensure that the cell layer integrity was 
preserved during the experiment. Fluorescein isothiocyanate (FITC)-labelled dextran of ~10-
kDa (FD10) was used as a model hydrophilic macromolecule and HEPES-buffered HBSS 
solution (pH 7.4) as a transport medium. 
FD10 sample was prepared by dissolving the FD10 powder in pre-warmed HBSS/HEPES 
solution (37°C) at 1 mg/ml. Cell culture medium was replaced with the transport medium 
(0.5 ml apically and 1.5 ml on the basolateral side) and cells incubated with the transport 
medium (HBSS/HEPES) at 37°C for ~30 min. TEER was measured again to ensure that the 
cell layers maintained their integrity in the transport medium. HBSS/HEPES was then 
UHPRYHG IURP WKH DSLFDO VLGH RI WKH FHOO OD\HUV DQG UHSODFHG ZLWK )' ȝJPO LQ
HBSS/HEPES). The Transwell® plate was covered with aluminium foil to protect it from 
light and the plate placed in the incubator (37°C). Basolateral solution was sampled 
SHULRGLFDOO\E\UHPRYLQJȝOHYHU\PLQDQGWUDQVIHUULQJWKHVROXWLRQLQWRDEODFN-
well plate and replaced. The sampled basolateral solution was replaced with the same volume 
of the transport medium. Permeability studies were conducted for a period of 3 hours. FD10 
was quantified by fluorescence with an MFX microtiter plate fluorometer (Dynex 
Technologies, USA) using FITC fluorescence parameters (485 nm excitation, 535 nm 
emission). The resulting fluorescence readings were converted into concentrations and finally 
amounts using calibration curves, which involved fluorescence measurements of known 
concentrations of serially diluted FD10. 
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To determine whether any changes in FD10 permeability following cytokine application 
result from a tight junction effect, permeability experiments were also conducted at 4°C. In 
this case, cell layers were treated with the cytokines (IL-4; 5ng/ml), (IL-13; 5ng/ml) and 
(TNF-Į QJPO IRU  GD\V &HOOV ZHUH WKHQ LQFXEDWHG ZLWK FROG +%66 DW & DQG
following FD10 application cells were transferred to a cold room at 4°C.  
FD10 permeability is expressed as apparent permeability coefficient (Papp), calculated using 
the following equation: 
 
 
Where: 
Papp: Apparent permeability coefficient (cm/s)  
ǻ4ǻW3HUPHDELOLW\UDWHȝJV 
A: Diffusion area of the cell layer (cm2) 
&R,QLWLDOFRQFHQWUDWLRQRI)'ȝJPO 
 
2.2.5  Confocal Microscopy Imaging of Tight Junction Protein, Zonula Occludens (ZO-
1) 
 
Initially, Calu-3 cell line was incubated with cytokines (IL-4; 5ng/ml), (IL-13; 5ng/ml) and 
(TNF-Į QJPO IRU  GD\V &RQIOXHQW &DOX-3 cells were then fixed with 3% w/v 
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paraformaldehyde by incubating for approximately 10 min at room temperature. Cells were 
then washed with PBS and permeabilised by incubating with Triton X-100 (0.1% v/v in PBS) 
for 10 min. PBS was used again to wash the cells and 1% w/v BSA (in PBS) applied for 1 
hour. This solution was then removed and mouse, anti-human ZO-1 (primary) antibody 
GLOXWHGLQ%6$3%6DWȝJPODSSOLHGWRWKHFHOOVIRURQHKRXU7KHSULPDU\DQWLERG\ZDV
aspirated and cells washed extensively with PBS. Rabbit, anti-mouse (secondary) antibody 
diluted according to the mDQXIDFWXUHU¶VLQVWUXFWLRQVLQ%6$3%6ZDVWKHQDSSOLHGWRWKH
cells for 1 hour. The secondary antibody was then removed and cells washed several times 
with PBS. The Transwell® membrane was then cut and placed on glass slides for confocal 
imaging. Cells nuclei were labelled with Hoechst 33342, whilst 1% 1,4-diazobicyclo-
[2,2,2]-octane (DABCO) in 90% glycerol/10% PBS was used as a mounting medium. 
Confocal imaging was conducted using a Leica TCS SP2 system mounted on a Leica 
DMIRE2 inverted microscope. 
 
2.2.6  Collection of Gene Microarray Data from GEO 
 
The microarray data of selected genes were collected from Gene Expression Omnibus (GEO) 
database (http://www.ncbi.nlm.nih.gov/geo). GEO database contains a platform which is the 
type of array used in the experiment. In total four studies were analysed and the difference in 
gene expression between healthy samples and asthmatic patients determined. More detailed 
information regarding the methodology employed for microarray data analysis is included in 
appendices 8.2 and 8.3. The series numbers of four studies used are listed in Table 2.1: 
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Table 2.1  Summary of four studies examined from GEO database. 
 
 
2.2.7  Statistical Analysis 
 
6WXGHQW¶VW-test was employed to the statistical significance of the data, with p values < 0.05 
considered as significant. 
Study Series Platform Sample number 
1 GSE470 GPL8300 12 (6 healthy, 6 asthmatic) 
2 GSE18965 GPL96 16 (8 healthy, 8 asthmatic) 
3 GSE4302 GPL570 26 (13 healthy, 13 asthmatic) 
4 GSE3212 GPL80 30 (15 healthy, 15 asthmatic) 
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Chapter 3 
Effect of Cytokines on Barrier Characteristics of Human Airway Epithelial Cell Layers 
(Calu-3) 
 
 
3.1  Introduction 
 
The airway mucosa is a biophysical barrier between the external environment (lumen) and 
submucosal tissues, playing an important role in protecting the lung and other tissues from 
harmful elements of the external environment by providing selective permeability [1][2][3]. 
Disruption of the functionality of this epithelial barrier may therefore lead to undesirable 
effects on the lung [4][5]. To study the influence of airway epithelial barrier disruption on 
pulmonary disease, or the influence of disease on the airway barrier, researchers have 
attempted to establish in vitro systems that mimic in vivo conditions in disease, with limited 
success [6]. 
 
In terms of employing in vitro models to study the mucosal barrier of the airways, the use of 
primary cells would be an ideal choice due to a closer representation of the tissue of interest 
[7]. However, due to associate disadvantages, as discussed in the Introduction chapter, 
laboratories currently mainly rely on the use of cancerous cell lines [8].  
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One of the principal cell lines for in vitro investigation of the airway mucosal barrier is the 
Calu-3 cell line [9][10]. This cell line is derived originally from the human bronchial 
submucosal glands [1][10]. The Calu-3 cell line is widely used as an in vitro model of the 
upper airways, including the bronchial [10] and nasal [11][12] mucosa, in studies related to 
investigation of the metabolic and permeability properties of the human airways. The key 
benefits of using the Calu-3 cell line as an in vitro model of the airways lies in the ability of 
these cells to grow as polarised layers with tight junctions when cultured appropriately [10]. 
In contrast, several other airway-originated cell lines fail to generate significant 
transepithelial electrical resistance (TEER, an indication of tight junction formation and 
µWLJKWQHVV¶ RI WKH WLJKW MXQFWLRQV in vitro [10]. Furthermore, Calu-3 cells are capable of 
producing mucus (when using specific culture conditions), which offers the possibility of 
studying the effect of mucus on drug permeability [1][13]. 
 
Studies determining the usefulness of the Calu-3 cell model for in vitro pulmonary drug 
absorption studies have generally shown that this model is associated with good in vitro-in 
vivo correlation [14]. In using the Calu-3 cell line as a model of the airway mucosa, the cells 
are typically cultured on permeable supports (e.g. Transwell® inserts). Although the use of 
permeable supports for Calu-3 culture is almost universal in studies employing these cells as 
a model of the airway barrier, other culture conditions used by different labs vary 
considerably. Calu-3 cells can be grown in vitro under liquid-covered culture (LCC), where 
cells are bathed by the culture medium on both apical (or luminal) and basolateral (or basal) 
sides. Calu-3 cells may also be cultured on permeable supports using air-interfaced 
conditions (AIC), where polarised cells are exposed to the culture medium on the basal side 
only [14]3UHVHQWO\WKHUHLVQRFRQVHQVXVRQWKHµFRUUHFW¶FXOWXUHFRQGLWLRQVWKDWSURGXFH in 
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vitro models that best resemble the in vivo tissue. Consequently, examples of Calu-3 culture 
using both LCC and AIC conditions can be found extensively in the literature. However, 
there is some evidence that Calu-3 culture using AIC achieves superior representation of the 
in vivo conditions, as compared to LCC [1][14][10]. A study comparing the two systems 
observed presence of mucus and an apically ciliated surface in the epithelial cell layer 
resulting from AIC, whilst there was less apparent mucus secretion and cilia presence in cells 
obtained from LCC conditions [14]. 
In improving our understanding of the inflammatory diseases of the lung, such as asthma, 
recent efforts have focused on studying the biology and physiology of the epithelium [2]. 
Remodelling of the respiratory epithelium is one of the crucial characteristic features of 
asthma [17]. The alteration in the structure of the epithelium in such inflammatory processes 
may, in turn, cause increased mucus secretion by relevant components of the mucosa (goblet 
cells), dysfunction of epithelial tight junctions and fibrosis [17]. 
As indicated in the Introduction chapter, this chapter seeks to determine the effect of TNF-Į
IL-4 and IL-13 proinflammatory cytokines on human airway epithelium in terms of mucosal 
barrier characteristics and permeability properties. 
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3.2  Methods 
 
3.2.1  Effect of Site-Specific Cytokine Addition on Epithelial Barrier 
3.2.1.1  Effect on TEER 
Calu-3 cells were used between passages 27-36. Cells were initially cultured on 75 cm2 flasks 
XQWLO FRQIOXHQW 7KHUHDIWHU FHOOV ZHUH GHWDFKHG µWU\SVLQLVHG¶ IURP WKH IODVNV VHHGHG RQ
Transwell® filters and cultured using AIC condition (following the protocols described in 
sections 2.2.1.1 and 2.2.1.2.1). TEER measurements were conducted every 2 days during a 3-
week culture period. A detailed description of the TEER measurement method is included in 
sections 2.2.2 and 2.2.3.  
 
3.2.1.2  Effect on FD10 Permeability 
3.2.1.2.1  )'3HUPHDELOLW\DWÛ& 
 
Calu-3 cells were cultured on Transwell® filters using AIC conditions. Only the cell layers 
GLVSOD\LQJ7((5YDOXHV!FP2 were included in this study. Recombinant human IL-4 
and IL-13 were applied to the cells at 5 ng/ml, whereas TNF-Į DW  QJPO LQ WKH FXOWXUH
medium. Each cytokine was added to the cell layers on the apical side only, on the basolateral 
side only, or on both apical and basolateral sides (i.e. bilaterally). A control experiment was 
conducted where the culture medium (without cytokines) was applied to the cells at the same 
time. TEER measurements were taken regularly for 3-4 days post sample application. 
Permeability experiments were conducted on 21 days. For this culture medium was replaced 
with transport medium (HBSS/HEPESÛ&&HOOVZHUHLQFXEDWHGIRUaPLQWRDGDSWto 
the new medium, and then TEER was measured again to confirm the adaptation. Half the 
volume of HBSS/HEPES was removed from the apical side and replaced by the same volume 
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of FD10 dissolved in warm HBSS/HEPES with (500 µg/ml) concentration. The rest of the 
experiment was described in more detail is section 2.2.4. 
 
3.2.1.2.2  )'3HUPHDELOLW\DWÛ& 
 
Calu-3 cells were cultured as AIC condition and incubated with (HBSS/HEPES) solution at 
Û&IRUDSSUR[LPDWHO\PLQ7KHVROXWLRQZDVWKHQUHSODFHGZLWK)'0 with concentration 
ȝJPO&HOOVZHUHSODFHGDWÛ&EHWZHHQVDPSOLQJLQWHUYDOV 
 
3.2.2  Effect of Cytokines on Zonula Occludens-1 Protein 
 
Calu-3 cells were grown on filters using AIC condition and imaged by confocal microscope 
after they formed polarised monolayers. Zonula Occludens-1 (ZO-1) staining was completed 
as using protocol described in more detail previously in section 2.2.5. 
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3.3  Results 
 
3.3.1  Effect of Site-Specific Cytokine Application on Calu-3 Barrier for 3 days 
3.3.1.1  Effect on TEER 
 
Changes in TEER of Calu-3 cell layers following site-specific addition of TNF-Į,/-4 and 
IL-13 are presented in Figure 3.1. Application of TNF-Į DW  QJPO )LJXUH D DW WKH
apical side of Calu-3 layers displayed no notable effect, as the changes in TEER were similar 
to those of control cell layers (where cytokine addition was omitted). In fact, an increase in 
TEER following apical addition of TNF-ĮZDVDSSDUHQW7KHUHDVRQVEHKLQGWKLVHOHYDWLRQLQ
TEER are not apparent, but control cell layers exhibited a similar trend.   
 
Basolateral application of TNF-ĮSURGXFHGDQ LQWHUHVWLQJSDWWHUQ LQ7((5$PHDVXUHPHQW
taken 24 hours following its application revealed an increase in TEER at this time point by 
approximately 50%, as compared to the baseline value. However, TEER recordings at later 
time points showed that TEER dropped, with values at 48 hours and 72 hours amounting to 
approximately 65% and approximately 57% of the baseline value, respectively.    
 
Figure 3.1b shows the TEER pattern ± measured over a three-day period ± of polarised Calu-
3 layers, following their treatment with IL-4 (applied as 5ng/ml). The changes in TEER 
followed a similar pattern to control cell layers, with an initial decrease to approximately 
65% of the baseline value, measured 4 hours after application, followed by a gradual 
increase. This trend was observed with both apical and basolateral addition of IL-4 and was 
also apparent with the control cell layers. TEER values at the final measurement point (72 
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hours) were approximately 87% and 82% of the baseline value with apical and basolateral IL-
4, respectively, but these values were not statistically different to control cell layers. 
 
Site-specific treatment of polarised Calu-3 cell layers with the third selected cytokine tested 
in this work, namely IL-13 (5 ng/ml), produced the effects shown in Figure 3.1c. Both apical 
and basolateral IL-13 additions resulted in TEER patterns closely resembling the control up 
to the 48 hours measurement interval. Although at the final measurement point TEER of cell 
layers treated with IL-13 on the basolateral side was approximately 94% of the baseline 
TEER, compared to both apical additions of IL-13 and control cell layers (approximately 
137% of baseline TEER), the t-test confirmed that TEER values of apical and basolateral 
sides applications are not statistically significantly different, compared to control (p= 0.1278 
and 0.8658, respectively).  
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Figure 3.1  TEER measurements of Calu-3 cells cultured on filters using AIC conditions 
and treated by a) TNF-ĮQJPOEIL-4 (5ng/ml), c) IL-13 (5ng/ml) for 72 hours. 
  
TEER is expressed as % change compared to accumulative value (baseline value). 
Background TEER due to the filter was subtracted from the reported TEER values. Data 
presented as the mean ± SD (n=4). Statistical analysis calculated by t-test (P value: ns >  
0.05).* indicates statistical difference.  
 
 
3.3.1.2  Effect on FD10 Permeability 
3.3.1.2.1  Permeability at 37oC 
 
In addition to TEER, changes in the permeability barrier of Calu-3 cell layers following four 
days exposure to cytokines were also evaluated by measuring the permeability of a 
macromolecular model compound. Figure 3.2 depicts FD10 permeability across polarised 
Calu-3 cell layers, after treatment with the cytokines on either the apical or basolateral side. 
FD10 permeability is expressed as apparent permeability coefficient (Papp), which was 
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calculated according to the equation described in section 2.2.4, following regular sampling of 
the basolateral solution (over 3 hours) and FD10 quantitation by fluorescence. FD10 
permeability across the cell layers was measured following treatment of confluent and 
polarised cell layers (apically or basolaterally) with the cytokines for 4 days.  
 
Figure 3.2a shows that FD10 permeability across the cell layers treated with TNF-ĮRQ WKH
apical side was in fact lower, compared to permeability across control cell layers without 
TNF-Į WUHDWPHQW Regarding FD10 permeability across polarised Calu-3 layers following 
their exposure to TNF-ĮRQWKHEDVRODWHUDOVLGH, the Papp value reached 2.3 x 10-8 cm/s, and 
with the control permeability of 1.2 x 10-8 cm/s, making this increase just outside the 
statistical significance (p= 1.992 and 2.306, respectively).  
 
The impact of cell treatment with IL-4, either apically or basolaterally, on their barrier (as 
measured in terms of FD10 permeability) is highlighted in Figure 3.2b. Prior treatment of 
cells layers with IL-4 on the apical side did not have an effect on permeability. Cells layers 
that were previously basolaterally treated with IL-4 displayed permeability of Papp 2.75 x 10-7 
cm/s), relative to control (Papp1.53 x 10-7 cm/s), but this difference in permeability did not 
reach a statistical significance (p= 1.864).  
 
FD10 permeability across polarised Calu-3 cell layers previously treated with IL-13 followed 
a similar pattern to those subjected to IL-4. Figure 3.2c reveals that both apical and basal cell 
treatment with IL-13 produced cell layers displaying permeability towards FD10 that was not 
statistically significantly different to control cell la
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Figure 3.2  Effect of 96 hours cytokine treatment on FD10 permeability across Calu-3 
OD\HUVDWÛ&([SRVXUHWRD71)-ĮQJPOE,/-4 (5 ng/ml) and c) IL-13 (5 ng/ml).  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which is described in section 2.2.4. Results presented as the mean ± SD (n=4). 
Statistical analysis calculated by t-test (P value: ns >  0.05). 
 
 
 
 
3.3.1.2.2  Permeability at 4oC 
 
To confirm that the change in permeability following cell treatment with the cytokines is due 
to an effect of cytokines on the tight junctions (and hence the paracellular barrier), FD10 
permeability experiments were conducted at Û&LQDGGLWLRQWRQRUPDOFell culture conditions 
Û&,QWKLVH[SHULPHQWDOVHW-up, the energy-requiring processes, including active transport, 
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would be inhibited and any increase in permeability is likely to result from changes in the 
passive transport (i.e. the paracellular corridor).  
 
The data in Figure 3.3 shows FD10 permeability across Calu-FHOO OD\HUVDWÛ&,Q)LJXUH
3.3a the cells were previously treated with TNF-ĮDWQJPOIRUGD\VDQGHTXLOLEUDWHGDW
Û&EHIRUHWKHH[SHULPHQW7KHGDWDJHQHUDOO\PLUURUWKHWUHQGVREVHUYHGDWÛ&ZLWKWKH
cell layers treated with TNF-ĮGLVSOD\LQJD ODUJHUSHUPHDELOLW\FRPSDUHGWRFRQWURO,QWKLV
instance, the cell layers exposed to TNF-Į RQ WKH EDVDO VLGH H[KLELWHG D ODUJHU )'
permeability (statistically significant) of 0.78 x 10-8 cm/s compared to control 0.33 x 10-8 
cm/s. In contrast, apical presence of TNF-ĮGLGQRWLQGXFHDVXIILFLHQW LQFUHDVHLQFHOO OD\HU
permeability (0.43 x 10-8 cm/s), versus control (0.33 x 10-8 cm/s), to reach statistical 
significance.   
 
Figure 3.3b shows FD10 permeability of IL-4-treated Calu-FHOOOD\HUVDVPHDVXUHGDWÛ&
The data shows no significant increase in permeability, regardless of the site of IL-4 
application (Papp, apical= 2.34 x 10-7 cm/s, basolateral= 3.86 x 10-7 cm/s, control= 2.97 x 10-7 
cm/s). A similar outcome was observed with IL-13 (Figure 3.3c), with no increases in cell 
OD\HUSHUPHDELOLW\DWÛ&IROORZLQJ,/-13 treatment either on the apical or basal side of the 
cell layers (Papp, apical= 4.12 x 10-7 cm/s, basolateral= 3.43 x 10-7 cm/s, control= 4.42 x 10-7 
cm/s).   
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Figure 3.3  Effect of 96 hours cytokine treatment on FD10 permeability across Calu-3 
OD\HUVDWÛ&([SRVXUH to a) TNF-ĮQJPOE,/-4 (5 ng/ml) and c) IL-13 (5 ng/ml).  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in section 2.2.4. Results presented as the mean ± SD (n=4). 
Statistical analysis calculated by t-test (P value: * <  0.05, ns >  0.05). 
 
 
3.3.2  Effect of Basolateral Cytokine Application on Cell Layer Barrier: a Comparison 
between Different Cytokines 
 
3.3.2.1  Comparison of Effect on TEER 
 
Previous experiments served to establish the experimental conditions that lead to more 
prominent effects of cytokines on Calu-3 layer barrier. Following the observation that basal 
application of the cytokines leads to a greater effect on the cell layer barrier (despite this 
effect not reaching statistical significance), in further experiments, described in the 
forthcoming sections, cytokines were always applied on the basolateral side of polarised cell 
layers.  
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The influence of cytokine application (on the basolateral side of the cells) on TEER is   
depicted in Figure 3.4. The data compares the effect of the three cytokines by showing TEER 
values before (baseline) and after cell incubation for four days. The present study highlights 
that out of the three tested cytokines, only the cell layers treated with TNF-ĮZHUHIRXQGWR
display a significantly lower TEER, compared to the baseline value before the treatment. 
When applied on basolateral side, TNF-ĮVKRZHGDGHFUHDVHLQWKH7((5YDOXHIURPa
to ~78%) 96 hours post treatment. Following IL-4 treatment the TEER value changed from 
(~115% to ~97%) as % of control value. Also, IL-13 provided no effect as TEER values 
changed from (~106% to ~117%). 
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Figure 3.4  TEER measurements of Calu-3 cells cultured on filters using AIC conditions 
and treated for 96 hours with cytokines (IL-4 and IL-13 at (5 ng/ml) and TNF-Į DW 
ng/ml).  
TEER is expressed as % of Control (Calu-3 without cytokines). Background TEER due to the 
filter was subtracted from the reported TEER values. Data presented as the mean ± SD 
(n=4). Statistical analysis calculated by t-test (P value: * <  0.05, ns > 0.05). 
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3.3.2.2  Comparison of Effect on FD10 Permeability 
3.3.2.2.1  Permeability at 37oC 
 
FD10 permeability across polarised Calu-3 layers treated basolaterally with TNF-Į,/-4 or 
IL-13 is shown in Figure 3.5. On this occasion, cells subjected to TNF-ĮRU,/-4 incubation 
exhibited a significantly larger permeability, compared to control (p < 0.001 and < 0.05, 
respectively). The largest effect on permeability was seen in TNF-Į-treated cells. Here the 
cell layers displayed a 3.6-fold larger FD10 permeability compared to control. Dextran 
permeability across IL-4-treated cell layers was 2.5-fold larger compared to control.  
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Figure 3.5  Effect of tested cytokines on FD10 permeability across Calu-OD\HUVDWÛ&
Cytokines treatment for 96 hours.  
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in Chapter 2. Results presented as the mean ± SD (n=4). 
Statistical analysis calculated by t-test (P value: * <  0.05, ** <  0.001, ns > 0.05). 
 
3.3.2.2.2  Permeability at 4oC 
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A comparison between different cytokines in terms of their effect on cell layer permeability 
DWÛ&LVSUHVHQWHGLQ)LJXUH7KLVVKRZV)'WUDQVSRUWDWÛ&DFURVV&DOX-3 layers AIC 
grown and pre-treated with several cytokines for 4 days. The figure below shows that the 
permeability in cold condition is much lower than in normal condition. At 4oC cell layers 
treated with TNF-Į ZHUH IRXQG WR GLVSOD\ D QRWDEO\ KLJKHU SHUPHDELOLW\ to FD10, 
approximately (Papp= 1 x 10-8 cm/s), amounting to 2-fold, compared to control with Papp= 
0.45 x 10-8 cm/s, (p <0.0001). IL-4 and IL-13 treated cells did not exhibit a significantly 
different permeability relative to control by showing Papp= 0.36 and 0.33 x 10-8 cm/s, 
respectively.    
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Figure 3.6  Effect of tested cytokines on FD10 permeability across Calu-OD\HUVDWÛ&
Cytokines treatment for 96 hours.  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in Chapter 2. Results presented as the mean ± SD (n=4). 
Statistical analysis calculated by t-test (P value: **** < 0.00001, ns >  0.05). 
 
 
3.3.2.3  Effect of Cytokine Application on ZO-1 
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In establishing the effect of cytokine treatment on Calu-3 layer barrier, changes in cell layer 
TEER and permeability to a model hydrophilic macromolecule were determined, as described 
above. In addition to these, immunostaining of a key tight junction protein, called zonula 
occludens-1 (ZO-1), was employed as a tool to test the possibility of structural changes in the 
tight junctions resulting from cytokine treatment. In this instance, only TNF-Į-treated cell 
layers were imaged based on the indications from the above experiments that this cytokine 
induces greater effects on the epithelial cell barrier. Figure 3.7 shows confocal micrographs 
of Calu-3 cells, immunostained for ZO-1 following their culture as polarised layers and 
treatment with TNF-Į for four days (3.7a) and control cell layers without cytokine treatment 
(3.7b). In both subfigures, ZO- VWDLQLQJ JUHHQ DSSHDUV LQ D W\SLFDO PDQQHU RI µEHOWV¶
surrounding adjacent cells (blue cell nuclei). While the general staining pattern is similar in 
both conditions, there appears to be a loss of staining intensity in cells treated with TNF-Į
Furthermore, under the latter conditions, the ZO- µEHOWV¶ DSSHDU VRPHZKDW GLVFRQWLQXHG
DUURZVFRPSDUHGWRFRQWUROFHOOVZKHUHDPRUHFRQWLQXRXVµFKLFNHQ-ZLUH¶-like network is 
apparent. 
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a) 
 
b) 
 
 
 
 
  
 
 
Figure 3.7  a) Immunostaining for ZO-1 tight junction protein in cell layers treated with 
TNF-ĮIRUIRXUGD\V  a) TNF- Įtreated cell layer and b) control cell layer.  
Blue: cell nuclei, Green: tight junction protein (ZO-1) distribution. Protocol described in 
section 2.2.5. Full image combines blue for cell nuclei and green for ZO-1 staining. 
 
 
3.3.3  Effect of Combined Cytokine Application on Calu-3 Layer 
3.3.3.1  Effect on TEER  
 
In the data presented so far, polarised Calu-3 cell layers were treated with one of the three 
tested cytokines and the effects on the cell layer barrier measured. To establish whether TNF-
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Į,/-4 or IL-13 potentially display a synergistic effect on the epithelial barrier, the cytokines 
were applied to the cell layers in combination and the parameters indicative of the barrier 
function measured.  
Figure 3.8 shows TEER changes after cell layers were incubated with the cytokines, added in 
combination, for four days. The following combinations of cytokines were added to the cells:  
TNF-Į,/-4, TNF-Į,/-13, IL-4 + IL-13 and TNF-Į,/-4 + IL-13. The data shows that 
with the exception of IL-4 + IL-13, all other tested conditions produced a marked reduction 
of TEER. The reduction in TEER amounted to 28%, 32% and 33% of control cell layers with 
the combinations of TNF-Į,/-4, IL-4 + IL-13 and TNF-Į,/-4 + IL-13, respectively (p < 
0.0001 in all instances). It should be noted that a significant decrease in TEER values was 
associated with presenting of TNF-ĮLQDQ\FRPELQDWLRQ7KHFRPELQDWLRQRI,/-4 and IL-13, 
not including TNF-ĮGLGQRWVKRZDVLJQLILFDQWHIIHFWRQ&DOX-3 layer TEER.  
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Figure 3.8  TEER measurements of Calu-3 cells cultured on filters using AIC conditions 
and treated by cytokines combinations (IL-4 and IL-13 at (5ng/ml) and TNF-ĮDWQJPO
for 4 days.  
 
TEER is expressed as % of Control (Calu-3 without cytokines). Background TEER due to the 
filter was subtracted from the reported TEER values. Data presented as the mean ± SD 
(n=4). Statistical analysis calculated by t-test (P value: * <  0.05, ** <  0.001, *** < 0.0001, ns 
>  0.05). 
 
 
3.3.3.2  Effect on FD10 Permeability 
3.3.3.2.1  Permeability at 37oC 
 
Figure 3.9 shows the permeability of FD10 across polarised Calu-3 layers previously treated 
with the combination of cytokines, as detailed in the previous section. The data shows that 
the combination of TNF-Į ZLWK ,/-4 exerted the most prominent effect on the cell layer 
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barrier. The increase in FD10 permeability (expressed as Papp) amounted to 2.6-fold, from 55 
x 10-8 cm/s to 143 x 10-8 cm/s, which was a statistically significant difference compared to 
the control cell layers (p < 0.05). Other combinations of cytokines did not produce significant 
increases in FD10 permeability.  
 
Pa
pp
u  1
0-
8
(cm
/s
)
0
50
100
150
200
IL-4 + IL-13
IL-4 + TNF-D
IL-13 + TNF-D
*
IL-4 + IL-13 + TNF-D
Control
ns
ns
ns
 Figure 3.9  Effect of combined cytokines treatment for four days on FD10 permeability 
across Calu-OD\HUVDWÛ&  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in section 2.2.4. Results presented as the mean ± SD (n=4). 
Statistical analysis calculated by t-test (P value: * <  0.05, ns >  0.05). 
 
 
3.3.3.2.2  Permeability at 4oC 
 
&RQGXFWLQJ WKH SHUPHDELOLW\ H[SHULPHQW DW Û& IROORZLQJ FHOO WUHDWPHQW ZLWK GLIIHUHQW
combinations of cytokines, is shown in Figure 3.10. Under the tested conditions, FD10 
permeability was significantly higher (compared to control) across the cell layers subjected to 
the following combinations of cytokines: IL-4 + TNF-Į,/-13 + TNF-ĮDQG,/-4 + IL-13 + 
TNF-Į7KHFRPELQDWLRQRI,/-4 and IL-13 displayed no significant effect on permeability.  
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Figure 3.10  Effect of combined cytokines treatment for four days on FD10 permeability 
across Calu-OD\HUVDWÛ&  
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in section 2.2.4. Results presented as the mean ± SD (n=4). 
Statistical analysis calculated by t-test (P value: * <  0.05, ** <  0.001, *** < 0.0001, ns > 
0.05). 
 
 
 
3.3.3.3  Effect of Treatment of Cells with Cytokine Combinations on ZO-1 
 
ZO-1 tight junction protein expression pattern was also determined following incubation of 
polarised Calu-3 cells with combinations of cytokines. The combinations of cytokines that 
produced most prominent effects on the cell layer barrier were investigated in the current 
experiment. These included the combination of TNF-ĮZLWK,/-4 (Figure 3.11a) and TNF-Į
with IL-13 (Figure 3.11b). The images reveal a somewhat lower staining intensity, which was 
also more discontinuous in cells treated with both combinations of cytokines, as compared to 
control cell layers (no cytokines treatment) (Figure 3.11c, also shown in Figure 3.7b).  
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a)  
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Figure 3.11  Immunostaning of TJs protein (ZO-1) of Calu-3 cells pre-treated with 
cytokines combinations for 4 days.  a) TNF-ĮQJPO,/-4 (5ng/ml) b) TNF-ĮQJPO
+ IL-13 (5ng/ml) c) Control cell layers not treated with cytokines.  
1RWHWKDWµQRWWUHDWHG¶LPDJHVZHUHDOVRVKRZQLQ)LJXUHE*UHHQLV=2-1 staining and 
blue is nuclear staining. Protocol described in section 2.2.5. 
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3.4  Discussion 
 
Evidence from recent studies has emerged that cytokines may play a key role in the 
progression of asthma [1][15] by remodelling the functionality and structure of airway 
epithelial barrier in asthmatics [16][17]. However, this research area is still at its beginning 
and there is insufficient knowledge on the mechanisms of how cytokines induce changes in 
the epithelium and the extent to which the epithelium is compromised. The present study was 
designed to determine the effect of three proinflammatory cytokines on the airway epithelial 
barrier. Work employed the Calu-3 cells, based on advantages offered by this cell line when 
employed as an in vitro model of the airways [18][19][20].  
Recent work investigating changes in the epithelium in asthma has suggested that the 
epithelium function as permeability barrier is compromised [21][22] and that this results from 
changes in the tight junctions. More specifically, down-regulation of tight junction proteins, 
including ZO-1, has recently been implicated in the epithelial dysfunction in asthma [23]. 
This disruption in epithelial barrier is thought to be mediated by the action of 
proinflammatory cytokines [23].  
Epithelial tight junctions are complex structures. They are composed of various proteins, such 
as occludin, claudin, JAM and ZO-1 [24] and have a critical role in maintaining the 
permeability barrier function of the epithelium [25]. Tight junctions are located at the apical 
side of epithelial cells and act as a gate, controlling the paracellular permeability [24]. The 
function of some tight junction components is still poorly understood [25]. 
 
Recent studies have shown that pro-inflammatory cytokines induce changes in the 
composition and structure of epithelial tight junctions and increase paracellular permeability 
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[26]. In this study to evaluate the effects of proinflammatory cytokines, TNF-Į,/-4 and IL-
13, on the airway barrier, formed polarised Calu-3 layers were treated with these cytokines 
for four days and the barrier properties tested by measuring TEER, macromolecular 
permeability and structural changes in the tight junctions. Initial experiments tested the 
conditions under which cell treatment with the cytokines produced most prominent changes 
in the epithelial barrier. For this the cytokines were applied on the apical, basolateral or both 
sides of the cell layers. The changes in TEER values and FD10 permeability induced in these 
conditions in this preliminary set of experiments were not significant, it was noted that 
basolateral application of the cytokines produced more notable effects compared to their 
apical addition. This observation can be explained by the presence of TNF-ĮUHFHSWRUVRQWKH
basolateral side of the airway epithelium [27]. It was therefore decided that in the subsequent 
set of experiments the cytokines were always applied on the basal side of the cell layers.  
 
The concentrations of cytokines employed in this study were initially optimised, with 
preliminary studies establishing the minimum doses of cytokines that cause maximum 
response on the epithelial barrier. The use of IL-4 and IL-13 at the concentration employed 
here (5 ng/ml) to induce inflammation was reported before [2], while TNF-ĮKDVEHHQXVHGLQ
such experiments at concentrations ranging from 5 ng/ml up to 100 ng/ml [27][28]. In the 
present work, TNF-ĮZDVXVHGDWQJPODIWHU LQLWLDOH[SHULPHQWVXVLQJ71)-ĮDW
and 50 ng/ml established that the epithelial barrier response was similar with 25 and 50 ng/ml 
(see appendix 8.1). 
 
Observation that TNF-ĮPD\H[HUWXQGHVLUDEOHHIIHFWVRQPXFRVDOEDUULHUKDVEHHQUHSRUWHG
previously [29] and this work appears to be in agreement It showed that cell layer treatment 
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with TNF-ĮDSSOLHGEDVRODWHUDOO\OHGWRDGHFUHDVHLQ7((5DQd this effect of TNF-ĮRQFHOO
layer TEER was reflected in the FD10 permeability study, where cell layers treated with this 
cytokine were more permeable to FD10, compared to control. To determine that the 
compromised barrier of the Calu-3 layers following TNF-ĮWUHDWPHQWUHVXOWV IURPDQHIIHFW
on the tight junctions, two further experiments were conducted: measurement of FD10 
SHUPHDELOLW\ DW Û& DQG LPDJLQJ WKH FHOOV IRU VWUXFWXUDO FKDQJHV LQ D NH\ WLJKW MXQFWLRQ
protein.  
 
Hydrophilic macromolecules pass across the epithelium by a combination of paracellular 
route and transcellular active transport processes, such as pinocytosis [30]. To establish that 
the increase in overall FD10 permeability following cytokine treatment results solely from 
changes in the paracellular barrier, additional FD10 permeability experiments were 
FRQGXFWHG DW Û& 8QGHU WKHVH FRQGLWLRQV WKH DFWLYH WUDQVSRUW URXWH ZLOO EH LQKLELWHG DQG
FD10 will traverse the cell layers paracellularly. Therefore, any increased FD10 permeability 
following cytokine treatment could be a result of changes in the paracellular barrier. 
Conducting these experiments was important considering that some groups have reported that 
transcellular transport of material across the epithelium is upregulated in inflammatory 
FRQGLWLRQVDIIHFWLQJWKHHSLWKHOLXPHJLQ&URKQ¶VGLVHDVH[31]. 
 
7KHGDWDUHYHDOHGWKDWDWÛ&)'SHUPHDELOity across Calu-3 cell layers treated with TNF-Į
was significantly higher compared to control. In fact the extent of permeability increase 
IROORZLQJF\WRNLQHWUHDWPHQWDWÛ&LVVLPLODUWRWKDWDWÛ&7KLVLQGLFDWHVWKDWWKH71)-Į
induced increase in epithelial permeability occurs through an effect on the paracellular 
pathway (i.e. the tight junctions). Furthermore, TNF-Į-treated cells displayed changes in the 
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appearance of ZO-1 tight junction protein. Together, the data may suggest that the increased 
permeability of Calu-3 cell layers by TNF-ĮDSSOLFDWLRQUHVXOWVIURPVWUXFWXUDOFKDQJHVLQWKH
epithelial tight junctions. The data is in agreement with previous reports that TNF-ĮSOD\VD
key role in remodelling the airway epithelium [32] by changing the expression of tight 
junction proteins such as ZO-1[25].  
 
The effect of IL-4 on the epithelial barrier is less clear. The present data suggest that, apart 
from a single instance where an increase in FD10 permeability was apparent, other 
experiments found that the change in permeability was not statistically significantly different, 
compared to control. IL-4 has been previously shown to affect the airway barrier by 
decreasing the expression of tight junction components, such as occludin and ZO-1 [2]. 
Finally, treatment of Calu-3 cell layers with IL-13 produced no significant effect on their 
properties, as indicated by non-significant changes in TEER and FD10 permeability. 
 
To examine whether the tested cytokines produce synergetic effects on the Calu-3 barrier, the 
cytokines were added to the cells in combinations. It was noted that all the combinations of 
cytokines containing TNF-Į 71)-Į  ,/-4, TNF-Į  ,/-13 and TNF-Į  ,/-4 + IL-13) 
produced significant effects on the Calu-3 barrier, as indicated by notable changes in TEER 
and FD10 permeability. The combination of cytokines which included TNF-Į OHG WR ODUJHU
effect on the cell layer barrier compared to individual application of the cytokines. The data 
therefore points to a synergistic effect of the cytokines on the mucosal barrier ± a 
phenomenon that has been reported previously in a study showing that the effects of TNF-Į
are most prominent when combined with other cytokines [33].  
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3.5  Conclusions 
 
The work in this chapter demonstrates that some proinflammatory cytokines produce 
epithelial barrier disruptive effects on airway Calu-3 cell layers and suggests that the 
mechanism of this disruption is related to actions on the tight junctions, including changes in 
ZO-1 distribution. The work contributes to our understanding of the role of cytokines on lung 
inflammatory disease. 
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Chapter 4 
Effect of Cytokines on Barrier Characteristics of Human Intestinal Epithelial Cell 
Layers (Caco-2) 
 
 
4.1  Introduction 
 
The intestinal epithelium is a biophysical wall that controls the absorption of nutrients and 
has a protective role by selectively limiting the passage of noxious elements from the external 
environment into the body [1][2][3][4]. In inflammatory bowel conditions such as Crohn`s 
disease and Ulcerative Colitis, the intestinal barrier has been reported to be defective and 
associated with paracellular leakiness [5][6]. A number of studies have demonstrated 
disruption of the tight junction complexes in Crohn`s disease [6][7]. This defective barrier 
capacity of the intestinal epithelium in inflammatory conditions therefore compromises the 
physiological function of the epithelium in preventing the passage of potentially harmful 
substances found in the intestinal lumen into the body [8]. In addition to an increased 
epithelial membrane permeability [2],  abnormally high mucus secretion is another feature of 
the inflamed intestinal epithelium [9].  
 
Proinflammatory cytokines have been shown to play a key role in remodelling of the 
intestinal mucosal barrier in inflammatory bowel conditions. In this respect, downregulation 
of tight junction protein ZO-1, leading to increased paracellular permeability of the intestinal 
epithelium has been reported [1][10][11]. Proinflammatory cytokines such as TNF-Į DQG
interleukins are therefore heavily involved in the progression of inflammatory bowel 
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disorders such as Crohn`s disease and Ulcerative Colitis [1][13]. Clinical investigations have 
documented that intestinal inflammatory diseases can be characterised by elevated levels of 
proinflammatory cytokines [10], which mediate remodelling leading to dysfunctional 
epithelial barrier [13]. Some proinflammatory cytokines were described in detail in sections 
1.1 and 3.1.  
The Caco-2 cell line used as a model of the intestinal epithelium is used widely in 
pharmaceutical research to study or predict the absorption of pharmaceutical agents and study 
intestinal disease [14][15][16][17]. The Caco-2 cell line expresses functional and 
morphological characteristics of human intestine [12] and it is used extensively due to the 
good in vitro-in vivo correlation provided by this model [17][18]. When cultured in vitro, the 
Caco-2 cell line has the ability to form tight junctions and express relevant components 
(found in vivo) such as transport and efflux proteins and brush border digestive enzymes 
[19][4]. 
 
This chapter assesses the effect of select cytokines on the epithelial barrier of the Caco-2 
monolayers, which were used as a model of the intestinal epithelium. Specifically, the 
influence of TNF-Į,L-4 and IL-13 on cell monolayer transepithelial electrical resistance and 
macromolecular permeability were investigated.  
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4.2  Methods 
4.2.1  Effect of Site-Specific Cytokine Addition on Epithelial Barrier  
4.2.1.1  Effect on TEER 
 
Caco-2 cells were used in this work between passages 46-76. Cells were routinely cultured on 
flasks (75 cm2, canted neck with vented caps) until confluence (cell coverage of flask surface 
by approximately 80-90%). Next, cells were detached from the flasks (by incubation with 
trypsin), seeded and subsequently cultured on Transwell® filters using liquid-covered culture 
conditions (following the protocols described in sections 2.2.1.1 and 2.2.1.2.1).  
TNF-Į,/-4 or IL-13 were applied to confluent Caco-2 monolayers at day 21 of culture on 
Transwell® supports. The cytokines were only applied to the cell monolayers expressing a 
7((5!ȍFP2, which was confirmed by measurement using an epithelial voltohmmeter 
(a detailed description of TEER measurement method is included in sections 2.2.2 and 2.2.4). 
TNF-ĮQJP/,/-4 (5 ng/mL) or IL-13 (5 ng/mL) were applied either on the apical side 
or the basolateral side of the cell monolayers. TEER was subsequently measured periodically 
during the period that the cell monolayers were treated with the cytokines, which was 3-4 
days.  
 
4.2.1.2  Effect on FD10 Permeability 
4.2.1.2.1  FD10 Permeability at 37ºC 
 
Caco-2 cells were cultured on Transwell® filters, as described previously. Only cell 
PRQROD\HUV GLVSOD\LQJ 7((5 YDOXHV ! FP2 were used in this study. Recombinant 
human IL-4 and IL-13 were applied to the cells at 5 ng/ml, whereas TNF-ĮDWQJPOLQWKH
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culture medium. The cytokines were added to the cells apically only, or on the basolateral 
side. A control experiment was conducted where the culture medium without the cytokines 
was applied to the cells at the same time. Permeability experiments were conducted following 
a 4-day cell treatment with cytokines and 21 day culture on Transwell® supports. FD10 
permeability experiments were conducted using HBSS/HEPES as the transport medium. 
Cells were initially equilibrated in HBSS/HEPES (for approximately 45 min) at 37ºC, 
followed by the addition of FD10 (in HBSS/HEPES at 500 µg/ml). Cells were placed in an 
incubator at 37ºC in between sampling periods. The general protocol for permeability 
experiment was described in section 2.2.4. 
 
4.2.1.2.2  FD10 permeability at 4ºC 
 
FD10 permeability at 4ºC was conducted in a similar way as at 37ºC. However, polarised 
Caco-2 monolayers (displaying 7((5 !  FP2) were initially equilibrated with 
HBSS/HEPES DW Û& IRU  PLQ )' ZDV WKHQ DSSOLHG LQ +%66+(3(6 DW Û& 
ȝJPODQGWKHFHOOVZHUHNHSWDWÛ&EHWZHHQVDPSOLQJLQWHUYDOV 
 
 
4.3  Results 
4.3.1  Effect of Site-Specific Cytokine Application on Caco-2 Barrier 
4.3.1.1   Effect on TEER 
 
Figure 4.1 shows the TEER of Caco-2 monolayers following the application of TNF-Į,/-4 
or IL-13 at either the apical or basolateral side of the cells. The addition of TNF-Į RQ WKH
apical side of the cell monolayers did not influence the TEER, as suggested by TEER values 
similar to the control condition (Figure 4.1a). However, following application on the 
Chapter 4                            Effect of Cytokines on Barrier Characteristics of Human Intestinal 
                                            Epithelial Cell Layers (Caco-2) 
 
79 
 
basolateral side of the cells, TNF-Į SURGXFHG D QRWDEOH GHFUHDVH LQ 7((5 WKLV HTXDWHG WR
approximately 61% of the baseline value after 96 hours of cell treatment. In the control 
experiment, TEER measurement at 96 hours amounted to approximately 102% of the 
baseline value. The difference in TEER values between basal TNF-ĮWUHDWPHQWDQGFRQWURODW
the final measurement point (96 hours) was statistically significant (p=0.018). 
Changes in Caco-2 monolayer TEER after treatment with IL-4 (applied at 5 ng/ml apically or 
basolaterally) is shown in Figure 4.1b. TEER of cell monolayers treated with IL-4 apically 
increased by approximately 45% (compared to the baseline value). Basolateral treatment 
provided a decrease in TEER to approximately 77% of the baseline figure 72 hours after 
treatment; however, TEER subsequently reversed to approximately 96% (of the baseline 
value), 96 hours post-IL-4 application. In control cell monolayers (i.e. those not treated with 
IL-4), TEER after 96 hours amounted to approximately 118% of the baseline value.  
 
Figure 4.1c depicts Caco-2 monolayer TEER over time after cell treatment with IL-13 (5 
ng/ml) for 4 days. Both apical or basolateral application of this cytokine showed no decrease 
in TEER. In fact, cell monolayer TEER increased notably during Caco-2 incubation with IL-
13 on the apical or basal side of the cells. A similar pattern was also observed with control 
cell monolayers. 
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Figure 4.1  TEER measurements of Caco-2 cells cultured on filters and treated by a) TNF-
ĮQJPOEIL-4 (5ng/ml), c) IL-13 (5ng/ml) for 96 hours.  
 
TEER is expressed as % change compared to initial value (baseline value). Background 
TEER due to the filter was subtracted from the reported TEER values. Data presented as the 
mean ± SD (n=4). Statistical analysis was calculated by t-test (P value: * < 0.05, ns >  0.05). 
 
 
 
4.3.1.2  Effect on FD10 Permeability 
4.3.1.2.1  Permeability at 37oC 
 
FD10 was measured after Caco-2 monolayers were treated with the cytokines for four days 
(i.e. under the same conditions as in the TEER study). The permeability of FD10 across the 
cell monolayers is expressed as apparent permeability coefficient (Papp), calculated using the 
equation described in section 2.2.4.  
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Figure 4.2a shows FD10 permeability across cell monolayers previously treated with TNF-Į
FD10 permeability across the cells treated with TNF-ĮRQWKHDSLFDOVLGHDPRXQWHGWR3app of 
approximately 1.5 X 10-8 cm/s, compared to that across control cell monolayers, which 
amounted to 1.01 X 10-8 cm/s; this difference was not statistically significant (p > 0.05). 
Conversely, Caco-2 monolayers treated with TNF-Į RQ WKH EDVRODWHUDO VLGH VKRZHG D
significantly higher FD10 permeability (Papp ~1.8 X 10-8 cm/s) compared to control (p = 
0.0076). 
Figure 4.2b shows FD10 permeability across the cell monolayers after their exposure to IL-4 
(5 ng/ml) for 4 days. IL-4 treated cell did not show an increase in FD10 permeability 
compared to control, as suggested by apparent permeability values of approximately 0.80 X 
10-8 cm/s and 0.98 X 10-8 cm/s, for apical and basolateral treatment, respectively, which were 
not statistically significant (p=0.21 and 0.39, respectively) compared to control. 
Likewise, cell monolayer treatment with IL-13 (5 ng/ml for 4 days) did not show notable 
effects on cell permeability to FD10, regardless of the site of application.  The data, shown in 
Figure 4.2c, show that FD10 permeability in cell monolayers treated with IL-13 apically or 
basolaterally amounted to approximately 2.8 X 10-8 cm/s and 3.2 X 10-8 cm/s, respectively. In 
both scenarios, the difference in permeability to control (Papp 2.3 X 10-8 cm/s) is insignificant 
(p = 0.5 and 0.9 for apical and basolateral IL-13 treatment compared to control, respectively). 
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Figure 4.2  Effect of a) TNF-Į QJPO E IL-4 (5ng/ml), c) IL-13 (5ng/ml) on FD10 
permeability across Caco-OD\HUVDWÛ&  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent 
permeability coefficient which described in 2.2.4. Results presented as the mean ± SD (n=4). 
Statistical analysis was calculated by t-test (P value: ** < 0.001, ns > 0.05). 
 
 
4.3.1.2.2  Permeability at 4oC 
 
To determine whether the alteration in permeability after cell treatment with the 
proinflammatory cytokines is due to an influence of cytokines on the tight junctions, 
additional FD10 permeability experiments were conducted at Û& ZKHUH DQ\ SHUPHDELOLW\
largely occurs through the paracellular corridor (active transport processes are inhibited). 
Figure 4.3 shows FD10 permeability across Caco-FHOOPRQROD\HUVDWÛ&IROORZLQJSULRU
cytokine treatment at normal cell culture condLWLRQVÛ&WUHDWPHQWRIFHOOPRQROD\HUVIRU
GD\V)LJXUHDGHSLFWV)'SHUPHDELOLW\DWÛ&DFURVV WKHFHOO PRQROD\HUVSUH-treated 
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with TNF-Į  QJPO %DVRODWHUDO WUHDWPHQW RI WKH FHOO PRQROD\HUV ZLWK 71)-Į GLG QRW
significantly alter the paracellular route, as indicated by non-significant difference between 
FD10 permeability in these conditions (0.91 x 10-8 cm/s) and control (0.35 x 10-8 cm/s; p = 
0.55). Caco-2 monolayers treated with TNF-ĮRQ WKHLUDSLFDOSROHGLVSOD\HGD ORZHU)'
permeability (0.101 x 10-8 cm/s) compared to control (p=0.0302).  
 
)LJXUH E VKRZV )' SHUPHDELOLW\ LQ FROG FRQGLWLRQV Û& PHDVXUHG DFURVV &DFR-2 
monolayers pre-treated with IL-4 (5 ng/ml). Polarised cells subjected to IL-4   basolaterally 
exhibited a significantly higher permeability (2.02 x 10-8 cm/s), as compared to control (0.35 
x 10-8 cm/s; p= 0.0005). On the other hand, apical treatment did not significantly affect the 
permeability under these conditions (Papp amounted to 0.48 x 10-8 cm/s; p= 0.1313, 
compDULVRQ ZLWK FRQWURO )' SHUPHDELOLW\ DW Û& DFURVV &DFR-2 monolayers pre-treated 
with IL-13 (5 ng/ml) is shown in Figure 4.3c. Apically-treated cell monolayers displayed 
FD10 permeability of 0.42 x 10-8 cm/s, whilst basolaterally-treated cells showed the 
permeability of approximately 1 x 10-8 cm/s. However, both these values are not statistically 
significantly different compared to control (p = 0.07 and 0.65, compared to control for apical 
and basolateral cytokine treatment, respectively).  
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Figure 4.3  Effect of a) TNF-Į QJPO E IL-4 (5ng/ml), c) IL-13 (5ng/ml) on FD10 
permeability across Caco-OD\HUVDWÛ&  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in 2.2.4. Results presented as the mean ± SD (n=4). Statistical 
analysis was calculated by t-test (P value: * < 0.05, *** <  0.0001, ns > 0.05). 
 
 
 
4.3.2  Effect of Basolateral Cytokine Application on Cell Layer Barrier: a Comparison 
between Different Cytokines 
 
4.3.2.1  Effects on TEER 
 
Based on the observation that the tested cytokines produce a larger effect on the epithelial 
barrier when applied on the basolateral side of polarised cells, in the further experiments 
(described in the subsequent sections of this chapter) cytokines were exclusively applied on 
the basolateral side of Caco-2 monolayers.  
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Figure 4.4 compares the effects of different cytokines (when applied to confluent Caco-2 
monolayers basally for 4 days) on TEER. The cytokines were used at the same concentrations 
as in the previous section, namely 25 ng/ml (TNF-ĮDQGQJPO,/-4 and IL-13). The data 
show TEER values before (baseline) and after basolateral cell incubation with the cytokines 
for four days. In this experiment, all cytokines were found to cause a significant decrease in 
Caco-2 monolayer TEER. Electrical resistance across the monolayers decreased by 
approximately 48%, 38% and 37% (compared to baseline values) after cell treatment with 
TNF-Į,/-4 and IL-13, respectively. 
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Figure 4.4  TEER measurements of Caco-2 cells cultured on filters and treated by 
individual cytokines {IL-4 and IL-13 at (5ng/ml) and TNF-ĮDW (25ng/ml)} for 4days.  
 
TEER is expressed as % of Control (Caco-2 without cytokines). Background TEER due to the 
filter was subtracted from the reported TEER values. Data presented as the mean ± SD 
(n=4). Statistical analysis was calculated by t-test (P value: * < 0.05, ns > 0.05). 
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4.3.2.2  Effects on FD10 Permeability 
4.3.2.2.1  Permeability at 37oC 
 
Figure 4.5 shows FD10 permeability across Caco-2 cells, previously treated with different 
cytokines basolaterally. Treatment with the cytokines did not produce a notable effect on cell 
monolayer permeability in this experiment: FD10 permeability was similar in all cases, 
equating to approximately 2.27, 3.78, and 3.78 X10-8 cm/s for TNF-Į,/-4 and IL-13-treated 
cells, respectively). The difference relative to control samples (whereby Papp amounted to 
2.65 X 10-8 cm/s) was not statistically significant in all cases (p > 0.05).  
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Figure 4.5  Effect of individual cytokines on FD10 permeability across Caco-2 layers at 
Û& 
 
 FD10 permeability is expressed as Papp, calculated using the equation of apparent 
permeability coefficient which described in 2.2.4. Results presented as the mean ± SD (n=4). 
Statistical analysis was calculated by t-test (P value: ns >  0.05). 
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4.3.2.2.2  Permeability at 4oC 
 
)LJXUHFRPSDUHV)'SHUPHDELOLW\LQFROGFRQGLWLRQVÛ&DIWHUFHOOWUHDWPHQWZLWKWKH
tested cytokines for 4 days. In the current experiment, cell monolayers treated with TNF-Į
IL-4 or IL-13 gave rise to FD10 permeability of 3.71, 2.12, and 1.11 x 10-8 cm/s, 
respectively. FD10 permeability in control conditions (where cytokines addition was omitted) 
was 5.37 x 10-8 cm/s. The data analysis shows that difference to cytokine treatment was not 
statistically significant in all cases.  
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Figure 4.6  Effect of individual cytokines on FD10 permeability across Caco-2 layers at 
Û&  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in 2.2.4. Results presented as the mean ± SD (n=4). Statistical 
analysis was calculated by t-test (P value: ns >  0.05). 
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4.3.3  Effect of Combined Cytokine Application on Caco-2 Barrier 
 
4.3.3.1  Effect on TEER 
 
Experiments presented in this section aimed to establish whether TNF-Į,/-4 or IL-13 exert 
a synergistic effect on the epithelial barrier of Caco-2 monolayers. The tested cytokines were 
therefore added to the cells in combination in the current experiments and TEER and FD10 
permeability measured. Specifically, the following combinations of cytokines were used: IL-
4 + TNF-Į,/-13 + TNF-ĮDQG,/-4 + IL-13 +TNF-Į 
 
Effect of cell treatment with the combinations of cytokines on cell monolayer TEER is shown 
in Figure 4.7. TEER values were measured twice, once at day 0 before cytokines addition and 
the second measurement was 4 days post cytokines treatment, and the results expressed as % 
of control value. The data demonstrate that when applied in any combination, the tested 
cytokines significantly decreased the cell monolayer TEER. The decrease in TEER with IL-4 
+ IL-13 combination amounted to approximately 60% (p <0.05). Presenting TNF-Į LQ DQ\
combination resulted in a marked decrease of TEER. This decrease was approximately 77%, 
89% and 104% in cell monolayers exposed to IL-4 + TNF-Į,/-13 + TNF-ĮDQG,/-4 + IL-
13 + TNF-ĮUHVSHFWLYHO\SLQDOOLQVWDQFHV  
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Figure 4.7  TEER measurements of Caco-2 cells cultured on filters and treated by 
combined cytokines [IL-4 and IL-13 at (5ng/ml) and TNF-ĮDWQJPO@ for 4 days.  
 
TEER is expressed as % of Control (Caco-2 without cytokines). Background TEER due to the 
filter was subtracted from the reported TEER values. Data presented as the mean ± SD 
(n=4). Statistical analysis was calculated by t-test (P value: * <  0.05, ** <  0.001, *** < 
0.0001, ns >  0.05). 
 
 
4.3.3.2  Effect on FD10 Permeability 
4.3.3.2.1  Permeability at 37oC 
 
Caco-2 monolayer permeability (to a macromolecular model, FD10) following treatment with 
a combination of three cytokines is shown in Figure 4.8. The data shows that the only 
combination that induced a significant effect on cell monolayer permeability was IL-4 with 
IL-13. In this instance, FD10 permeability amounted to approximately 3.4 x 10-8 cm/s, 
compared to untreated (control) cell monolayers, which displayed FD10 permeability of 
approximately 0.8 x 10-8 cm/s. The other tested combinations of cytokines failed to 
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significantly influence Caco-2 monolayer permeability, with observed FD10 permeability 
ranging from 0.9 - 1.2 x 10-8 cm/s with other tested combinations. 
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Figure 4.8  Effect of combined cytokines on FD10 permeability across Caco-2 layers at 
Û&  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in 2.2.4. Results presented as the mean ± SD (n=4). Statistical 
analysis was calculated by t-test (P value: * < 0.05, ns > 0.05). 
 
 
4.3.3.2.2  Permeability at 4oC 
 
Figure 4.9 shows FD10 permeability across Caco- PRQROD\HUV DV PHDVXUHG DW Û&
following cell treatment with different combinations of cytokines (for 4 days). It is apparent 
from the figure that FD10 permeability was similar in all the tested conditions and there was 
no significant increase in permeability following cell treatment with the cytokines.  
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Figure 4.9  Effect of combined cytokines on FD10 permeability across Caco-2 layers at 
Û&  
 
FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient which described in 2.2.4. Results presented as the mean ± SD (n=4). Statistical 
analysis was calculated by t-test (P value: ns >  0.05). 
 
 
4.4  Discussion 
 
Inflammatory bowel disease has been linked to an upregulation of proinflammatory 
cytokines, which play a significant function in mediation of inflammation [20][9]. 
Furthermore, it has been demonstrated that the intestinal barrier in certain inflammatory 
conditions is disrupted, whereby the permeability of harmful substances from the intestinal 
lumen across the gut wall [21][22]. The extent to which the intestinal barrier is compromised 
in inflammation is not known and was the focus of this chapter. Proinflammatory cytokines, 
IL-4, IL-13, and TNF-Į ZHUH XVHG DV µLQGXFHUV¶ RI LQIODPPDWLRQ LQ LQWHVWLQDO &DFR-2 
monolayers and the effect on their barrier determined.   
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In normal non-pathological state, the intestinal epithelium provides a robust biophysical gate, 
enabled by structural features such as the tight junctions, preventing non selective absorption 
of material, including potentially toxic elements, across the gut wall [23][8]. However, one of 
the main features of some intestinal inflammatory diseases is modulation of tight junction 
structure and function, leading to increased passage of noxious substances across the 
epithelium [24] 7KH LQWHVWLQDO HSLWKHOLXP KDV EHHQ VKRZQ WR EH µOHDN\¶ LQ LQIODPPDWRU\
disease states such as Crohn`s disease [23]. Recent research has suggested that the changes in 
epithelial barrier in such conditions arise from dysfunctional tight junctions, which in turn are 
affected by the action of proinflammatory cytokines, including TNF-ĮDQG LQWHUOHXNLQV[24] 
[21].  
 
This work assessed the effects of three proinflammatory cytokines, namely TNF-Į,/-4 and 
IL-13, on the epithelial barrier of intestinal Caco-2 cells. The cells were cultured as polarised 
monolayers ± a popular use of Caco-2 cells.  Cell monolayers were treated with these 
cytokines and the epithelial barrier tested by measuring TEER and macromolecular 
permeability. Caco-2 monolayer treatment with TNF-ĮOHGWRDVLJQLILFDQWGHFUHDVHLQ7((5
when applied on the basolateral side of the cells, whilst no significant effect was observed 
when TNF-ĮZDVSUHVHQWHGRQWKHDSLFDOVLGHRISRODULVHGFHOOPRQROD\HUV7KHGHFUHDVHLQ
TEER after cell treatment with TNF-ĮLVH[SHFWHGWREHDUHVXOWRIEDUULHUG\VIXQFWLRQHJ
an effect on the tight junctions) rather than cell death, which would result in dramatically 
reduced TEER [21]. A similar influence of TNF-Į RQ &DFR-2 monolayer TEER has been 
shown previously [23][21][22].  
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The pattern of TEER data was somewhat reflected in the permeability study, whereby FD10 
permeability across Caco-2 monolayers following a 4-day treatment with TNF-Į DSSOLHG
basolaterally, increased (this increase was significant in one experiment and in another failed 
to reach statistical significance). The observed inverse relationship between TEER and 
permeability is expected [23]FRQVLGHULQJWKDWERWKSDUDPHWHUVPHDVXUHWKHµWLJKWQHVV¶RIWKH
epithelial barrier. Apical treatment of the cell monolayers with TNF-Į GLG QRW DIIHFW WKH
permeability. The influence of cytokines on the epithelial barrier when added basolaterally 
and the lack of effect following apical exposure has also been reported previously [21]. This 
observation may be related to the basolateral presence of cytokine receptors in epithelial cells 
[21]. 
 
Several investigations have implicated TNF-Į DV D PHGLDWRU RI FKDQJH LQ WKH EDUULHU
properties of intestinal epithelium, increasing the permeability of tight junctions in bowel 
disease [25]. The mechanism of influence of TNF-ĮRQHSLWKHOLDOEDUULHUKDVEHHQVXJJHVWHG
to be the down-regulation of occludin and up-regulation of claudin proteins [26]. For 
example, the down-regulation of occludin expression has been reported in numerous patients 
suffering from inflammatory bowel disease [26]. Moreover, a recent study has demonstrated 
elevated expression of claudin in patients with Crohn`s disease [22]. Another change shown 
to occur in the inflamed epithelium, which is mediated by TNF-ĮUHODWHVWRWKe myosin light 
chain kinase (MLCK) protein, which is heavily involved in tight junction regulation [2]. Up-
regulation of TNF-Į LQ LQIODPPDWRU\FRQGLWLRQVFRXOGVWLPXODWH0/&.SURWHLQH[SUHVVLRQ
opening the tight junctions [13]. TNF-Į KDV WKH FDSDFLW\ WR LQGXFH QXFOHDU IDFWRU NDSSD %
(NF-ț%ZKLFKPD\DFWWRLQFUHDVHWKHH[SUHVVLRQRI0/&.[22]. The stimulation of MLCK 
expression led to increased paracellular permeability in Caco-2 monolayers [23]. 
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Furthermore, TNF-Į LQKLELWRUV VXFK DV F\FORKH[LPLGH FRXOG GHFUHDVH 0/&. H[SUHVVLRQ
and lower the permeability across intestinal epithelium [13].  
 
The two interleukin-based cytokines, IL-4 and IL-13 share the same receptors and studies 
have shown that they also share similar physiological roles [10]. Both IL-4 and IL-13 have 
capacity to bind IL-5Į,/-5Į FRPSOH[ ZKLFK VWLPXODWHV LQIODPPDWLRQ UHDFWLRQ LQ
numerous diseases [27]. IL-4 was previously reported to produce an increase in intestinal 
permeability and produce changes in the tight junctions, including decreased ZO-1 and 
occludin expression and increased expression of claudin-2 [22]. In this work, IL-4 and IL-13 
did not display a significant effect on cell monolayer TEER and FD10 permeability. It is 
presently unclear why the data in this thesis did not confirm the previous findings with 
regards to the effect of IL-4 and IL-13 on intestinal barrier, though this work employed a 
FDQFHURXV FHOO OLQH ZKLFK PD\ EH PRUH µUHVLVWDQW¶ WR WKH DSSOLFDWLRQ RI F\WRNLQHV DV
compared to primary cells or the tissue in vivo.  
 
&RQGXFWLQJ WKH SHUPHDELOLW\ VWXGLHV DW Û& ZDV SHUIRUPHG ZLWK WKH YLHZ RI REWDLQLQJ
mechanistic information on the action of the cytokines on the intestinal Caco-2 monolayers. 
Inhibiting the active transport route in these conditions would leave the passive route via the 
paracellular space as the only means for FD10 to traverse the cell monolayers. Any increase 
in FD10 permeability following cell treatment with the cytokines therefore would indicate a 
tight junction effect rather than an upregulated active transport route. This is particularly 
important as active transport processes such as transcytosis have been shown to occur in 
inflammatory bowel disease [28]3HUPHDELOLW\VWXGLHVDWÛ&ZLWKLQGLYLGXDOF\WRNLQHVZHUH
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somewhat inconclusive, showing a non-significant effect in FD10 permeability with TNF-Į
and IL-13, whilst IL-4 demonstrated a significant effect in one study. 
 
The most significant effect on the Caco-2 epithelial barrier was provided by application of 
cytokines in combination. This method of cell treatment, where epithelial cells are exposed to 
DµFRFNWDLO¶RIF\WRNLQHVSUREDEO\PRVWFORVHO\UHIOHFWVWKHin vivo conditions in inflammatory 
bowel disease. All the combination of cytokines produced a significant decrease in Caco-2 
monolayer TEER. The level of this decrease was notably larger than that with individual 
application of the cytokines. This synergetic effect on the epithelium resulting from the 
combined application of has been shown with IL-4 and IL-13 when combined with TNF-Į
[29]. Regarding the permeability of FD10 across the cell monolayers exposed to the 
combination of cytokines, IL-4 with IL-13 was the only combination that significantly 
increased FD10 permeability. It is not clear why other combinations did not produce a 
significant effect RQSHUPHDELOLW\,WLVDOVRQRWNQRZQZK\ZKHQPHDVXUHGDWÛ&WKHUHZDV
no significant increase in FD10 permeability with all the combination of cytokines. This is 
especially the case considering the large effect on TEER. However, it may be that TEER is a 
more sensitive indicator of tight junction opening compared to permeability, especially 
considering the relatively large molecular weight of FD10 (approximately 10 kDa). 
 
In addition to changes in tight junction permeability, inflammatory bowel disease is also 
associated with other tissue abnormalities such as defects in mucin expression [1] and the 
thickness of epithelium [1][30]. Recent research stated that proinflammatory cytokines also 
play a crucial function in the regulation mucin secretion and therefore the thickness of 
mucosal wall [1]. Clinical trials have shown that anti-TNF-ĮDQWLERGLHVVLJQLILFDQWly decrease 
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the progress of inflammatory intestinal disorders such as Crohn`s disease and ulcerative 
colitis [31][32]. The FDA-approved anti-TNF-ĮLQIOL[LPDEKDVEHHQVKRZQWRHQKDQFHWKH
intestinal barrier healing and improve the status of intestinal epithelium in inflammatory 
disorders [33][34]. Whilst reversing the changes in the epithelium in inflammatory disease 
states is essential for disease treatment, exploiting the defective barrier function of the 
intestinal epithelium in inflammation could be useful in delivering macromolecular 
therapeutic agents such as proteins non-invasively.  
 
4.5  Conclusion 
 
Of the tested cytokines, TNF-Į DQG ,/-4 produced some effects on the Caco-2 monolayer 
barrier when applied on the basal side of the cells, whilst apical treatment had no influence. 
The largest effect on the cell monolayer barrier was seen when the cytokines were added to 
the cells in combination, showing synergy.  
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5.1  Introduction 
 
Inflammatory disorders, such as asthma and irritable bowel disease, are commonly 
characterised by the presence of chronic lesions in the epithelial tissue [1][2][3]. In 
FRQMXQFWLRQZLWKWKHSUHVHQW LQIODPPDWLRQUHDFWLRQ WKHµOHDNLQHVV¶RIHSLWKHOLDOPXFRVDKDV
been reported as one of the symptoms [4][3][5]. The epithelial lesions are believed to mainly 
be a result of the effects of inflammatory mediators which induce remodelling of epithelial 
structure and its function [6][7]. It has been shown that endogenous inflammatory mediators 
play an important function in stimulating the inflammation responses in different tissues of 
the human body, including pulmonary and intestinal epithelium [8][9]. The presence, and 
intensity, of inflammatory reaction can cause permanent damage of epithelium 
[2][7][10][11]. The recent papers attribute a disruption in epithelial barrier properties (the 
µOHDNLQHVV¶WREHDFRQVHTXHQFHRIGDPDJHVWRWKHWLJKWMunctions, as the essential component 
of paracellular transport pathway [12][13][14]. With regards to described inflamed cells 
behaviour in vivo, damaged tight junction complex was observed in several respiratory [15] 
and intestinal studies [16].  
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Pro-inflammatory cytokines have been found involved as key players in the mechanism of 
inflammation reaction [7][17][18]. Cytokines are proteins released by wide varieties of cells, 
and they contribute to the intracellular communication and immunological responses 
[19][20]. For this project it is important to note that pro-inflammatory cytokines such as 
interleukin-4 (IL-4) [17], interleukin-13 (IL-13) [21] and tumour necrosis factor-alpha (TNF-
Į [22] were found to stimulate in vivo dysfunction of epithelium [12]. In several 
inflammatory disorders (e.g. asthma and Crohn`s disease) cytokine exposure was reported to 
result in modification of epithelial properties [7][12][18].  
 
In previous Chapters 3 and 4, formed Calu-3 and Caco-2 cell layers were treated for a short-
time period with cytokines (for 4 days), to potentially represent acute inflammation 
conditions. These were assessed in terms of epithelial permeability and tight junction 
structure. The transepithelial resistance (TEER) and permeability results demonstrated the 
influences of cytokines tested on epithelial mucosa, particularly tight junctions. The results 
shown in previous chapters were obtained following a 4 days treatment of formed cell layers 
with IL-4, IL-13, TNF-Į RU WKHLU FRPELQDWLRQV +Rwever, these studies did not probe the 
effect that a prolonged exposure to cytokines has on epithelial cell layers in vitro. Therefore, 
effects of prolonged exposure time of the mucosal cells to the cytokines on epithelial layers 
properties would be investigated in this chapter. This is aimed to better represent chronic 
inflammation conditions. 
 
Currently, a number of publications from research laboratories are attempting to design well-
characterised in vitro model that closely represent inflamed epithelial tissue [2]. Due to the 
difficulties of using in vivo models to study the effect of cytokines on epithelium [2][23][24], 
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designing representative in vitro models would be a good approach. Since the remodelling of 
epithelial structure in lung [25] and intestinal diseases [7] is assumed to be due to chronic 
inflammation reaction, the effect of chronic / prolong presence of pro-inflammatory cytokines 
with the epithelial monolayers seem necessary to study. Prolonged treatment of Calu-3 and 
Caco-2 cells with cytokines could lead to a design of practical in vitro model for respiratory 
and intestinal inflammatory disorders.  
 
Therefore, this chapter examines the effect of long-term pro-inflammatory cytokines 
treatment (21 days) on epithelial cell layer formation and properties with the aim to expand 
our understanding of a contribution of cytokines on inflammatory responses in epithelium 
and to investigate the chronic effect of cytokines on epithelium. 
 
5.2  Methods 
 
5.2.1  Effect of Cytokines on Calu-3 and Caco-2 TEER 
 
Calu-3 and Caco-2 cell lines were plated in 75 cm2 flasks with passage numbers 37 and 76, 
respectively. After confluence, cells were seeded on Transwell®  PP GLDPHWHU ȝP
pore size) at 100.000 cells/cm2 seeding density. Calu-3 cells were typically used as air-
interfaced culture (AIC), whereas Caco-2 cells were cultured normally as liquid-covered 
culture (LCC). EMEM medium was used for Calu-3 cells, while Caco-2 was cultured in 
DMEM medium, and the medium replaced every 2 days. Cell polarised layers integrity was 
identified by measuring the transepithelial electrical resistance (TEER). A detailed 
description of TEER measurement method is included in sections 2.2.2 and 2.2.4. 
 
Chapter 5       Effect of Long-Term Cytokines Treatment on Barrier Characteristics of Human   
Airway and Intestinal Epithelial Cell Layers 
106 
 
 
5.2.2  Effect of Cytokines on Calu-3 and Caco-2 Permeability 
 
Recombinant human pro-inflammatory cytokines IL-4, IL-13 (5ng/ml), and TNF-ĮQJPO
were applied on the basolateral side of Calu-3 and Caco-2 cells. Only the cell layers 
GLVSOD\LQJ7((5YDOXHV!DQG !FP2, for Calu-3 and Caco-2 respectively, were 
included in this study. Cells were exposed to cytokines for 21 days (the time needed by cells 
to form polarised monolayers). In further experiments, cells were treated with TNF-Į WKH
cytokine that provided the most effect on epithelial barrier as shown in earlier chapters) for 
short-term (4 days) to compare with long-term condition. Control cells were conducted 
without cytokine treatment. FD10 transport permeability studies were conducted on day 21 in 
culture after TEER confirmed that cells formed confluent membranes. Cells were firstly 
equilibrated in warm (HBSS/HEPES Û& VROXWLRQ WKHQ FHOOV LQFXEDWHG IRU aPLQ WR
adapt with transport medium and TEER was measured again to confirm cells situation. FD10 
solution was replaced with the half-DSLFDOPHGLXPDWFRQFHQWUDWLRQȝJPO7KHUHVWRI
experiment was described properly and in more information in 2.2.4. 
 
 
5.3  Results  
5.3.1  Effect of Long-Term Cytokines Application on Calu-3 and Caco-2 Barrier 
Properties 
5.3.1.1  Effect on TEER 
The effect of long-term cytokines treatment on TEER of Calu-3 and Caco-2 cell layers 
following the basolateral side addition of TNF-Į,/-4 and IL-13 is presented in Figure 5.1. 
Figure 5.1a shows the effect of long-term cytokines treatment on TEER of Calu-3 cells 
grown at air-liquid interface. From the results for control cells, it should be noted that the 
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TEER during the culture gradually increased to approximately 288% of the initial/baseline 
value (average TEER value at day 0 before cytokines addition and taken as 100%). During 21 
days of TNF-Į H[SRVXUH 7((5 YDOXHV JUDGXDOO\ LQFUHDVHG WR DSSUR[LPDWHO\  RI WKH
baseline value as the cell layer was formed. For IL-4 and IL-13 addition, the values reached 
approximately 148% for IL-4 and 164% for IL-13 treatment. The statistical analysis, which 
was conducted by t-test for each condition comparing with the control, indicated that the 
changes in TEER values are not significant in all of pro-inflammatory cytokines treatment 
conditions (P values >0.05), comparing to the results of control cells.  
Figure 5.1b shows the TEER measurements for Caco-2 cell culture during the 21 days 
exposure experiment. The results are expressed as percentage of baseline value (average 
TEER value at day 0 before cytokines addition and taken as 100%). Caco-2 control cells 
showed normal growth during the experiment (optical microscopy observation), and the 
TEER value rose gradually from 100% of the initial measurement to approximately 470% at 
the last day of experiment. In IL-4 and IL-13 conditions, TEER values were increased 
gradually from 100% to about 350% and 360%, respectively. T-test of significance confirmed 
that the changes in TEER values for both IL-4 and IL-13 interleukins are not significant in 
comparison to the control (P values >0.05). However, in TNF-Į FRQGLWLRQ LW LV FOHDU WKDW
during the culture period TEER values are significantly lower than that of the control cells, 
increasing to only approximately 175% in the final measurement. Statistical analysis by t-test 
demonstrated that P value in this case is less than 0.00001, confirming statistically significant 
difference. 
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Figure 5.1  TEER profiles of a) Calu-3 and b) Caco-2 cells cultured on Transwell® filters 
and treated for 21 days with IL-4, IL-13 (5ng/ml) and TNF-ĮQJPO 
 
TEER is expressed as % change compared to baseline value (TEER at day 0 before cytokines 
addition). Background TEER due to the filter was subtracted from the reported TEER values. 
Data presented as the mean ± SD (n=4). Statistical analysis calculated by t-test (P value: * <  
0.05, ** < 0.001, *** < 0.0001, **** <  0.00001 ns >  0.05). 
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5.3.1.2   Effect on Cell Layers Permeability 
 
In addition to TEER, changes in the permeability barrier of Calu-3 and Caco-2 cell layers 
following long-term cytokine exposure were evaluated by measuring the permeability of a 
macromolecular model compound, FD10. Figure 5.2 depicts FD10 permeability across 
polarised Calu-3 (grown at air-liquid interface) and Caco-2 cell layers, after a basolateral side 
treatment with the cytokines for 21 days. FD10 permeability is expressed as apparent 
permeability coefficient (Papp), which was calculated according to the equation described in 
section 2.2.4, following regular sampling of the basolateral solution (over 3 hours) and FD10 
quantitation by fluorescence, as described in section 2.2.4. 
Figure 5.2a shows the Papp values of Calu-3 cells treated with the cytokines. The apparent 
permeability of control cells was Papp ~ 55 ± 26 x 10-8 cm/s, while treated cells showed Papp ~ 
33 ± 8 x 10-8 cm/s for IL-4, Papp ~ 53 ± 10 x 10-8 cm/s for IL-13 treated and Papp ~ 32 ± 4 x 
10-8 cm/s for TNF-ĮH[SRVXUH$OOWKHVHYDOXHVVKRZHGLQVLJQLILFDQWGLIIHUHQFHRIORQJ-term 
cytokines treatment on Calu-3 cells permeability (P values >0.05) compare to the control. 
Figure 5.2b shows the effect of long-term cytokines treatment on the permeability of FD10 
across Caco-2 monolayers. Control cells which were not treated with cytokines showed Papp 
of approximately 2 ± 1 x 10-8 cm/s, with IL-4 and IL-13 treated cells showing Papp around 7± 
6 and 3 ± 1 x 10-8 cm/s, respectively. Statistical tests confirmed that both IL-4 and IL-13 
LQWHUOHXNLQ¶VUHVXOWVZHUHQRWVLJQLILFDQWO\GLIIHUHQWIURPWKHFRQWURO3app (p values >0.05). In 
TNF-Į VLWXDWLRQ WKH 3app result demonstrated that FD10 permeability is approximately 17-
times more than normal, untreated Caco-2 cells. Papp of FD10 was increased from around 2 
±1 x 10-8 in the control to around 38 ± 10 x 10-8 cm/s with TNF-Į WUHDWPHQW DQG W-test 
confirmed statistical difference (p value <0.00001). 
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Figure 5.2  Effect of long-term cytokines treatment on FD10 permeability across a) Calu-
3 and b) Caco-2 monolayers  
 
Cells were treated with IL-4, IL-13 (5ng/ml) and TNF-Į QJPO )' SHUPHDELOLW\
expressed as Papp, calculated using the equation of apparent permeability coefficient that 
described in section 2.2.4. Results presented as the mean ± SD (n=4). Statistical analysis 
calculated by t-test (P value: **** <  0.00001, ns >  0.05). 
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5.3.1.3  Comparing Long-Term and Short-Term Treatment with TNF-Į(IIHFWRQ
Permeability 
 
To compare the difference between the effects of long and short-term application of 
cytokines on epithelial layers permeability, in a new experiment the FD10 transport across 
the cell layers in these experimental conditions was determined. Figure 5.3a shows a 
comparison between Papp of FD10 transport across Calu-3 layers (grown at air-liquid 
interface) in long-term (21 days) and short-term treatment (4 days). In 3 weeks of TNF-Į
treatment experiment, the result shows that this cytokine produced a significant effect on 
Calu-3 layer permeability with Papp around 62 ± 17 x 10-8 cm/s comparing to control of 0.8 ± 
0.5 x 10-8 cm/s. However, short-term treatment did not provide a notable change in Calu-3 
permeability showing Papp of ~ 1.1 ± 0.4 x 10-8 cm/s. Taken together, the permeability in 
long-term treatment was approximately 77.5-fold higher than the control cell layer, while 
short-term TNF-Į H[SRVXUH ZDV RQO\  WLPHV PRUH WKDQ WKH FRQWURO 6WDWLVWLFDO DQDO\VLV
indicates that the result in long-term treatment are significantly different (p value < 0.001), 
and insignificantly increased in short-term treatment (P values >0.05), relative to the control. 
Figure 5.3b shows a comparison between Papp of FD10 transport across Caco-2 monolayers in 
long-term treatment (21 days) and short-term treatment (4 days). Again the long-term 
treatment provided significant effect by showing Papp of 14.5 ± 6.5 x 10-8 cm/s in long-term 
treatment, comparing to control Papp of 1.0 ± 0.2 x 10-8 cm/s. This means that the increase in 
permeability was nearly 14 fold. With regard to short-term treatment, apparent permeability 
coefficient Papp was approximately 2.5 ± 1.2 x 10-8 cm/s, and by comparing this value with 
the Papp of control Caco-2 cells, the permeability is 2.5 times increased. T-test demonstrated 
that the Papp in long-term exposure is significantly increased (p value <  0.05), relative to the 
control, while Papp in short-term experiment showed no statistical difference to the control.  
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Figure 5.3  Comparison of the effect of long-term and short-term TNF-Į QJPO
treatment on FD10 permeability across a) Calu-3 and b) Caco-2 monolayers. 
 
 FD10 permeability expressed as Papp, calculated using the equation of apparent permeability 
coefficient that described in section 2.2.4. Results presented as the mean ± SD (n=4). 
Statistical analysis calculated by t-test (P value: * <  0.05, ** <  0.001, *** < 0.0001, **** < 
0.00001, ns >  0.05). 
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5.4  Discussion 
 
The present work aimed to assess a possible difference between the effects of long-term and 
short-term proinflammatory cytokines treatments on epithelial monolayers properties. 
Chapters 3 and 4 discussed the short-term effects in more details, and this chapter will focus 
on the long-term effects. Epithelial cells were shown to have the ability to release cytokines 
in inflammatory conditions [26]. It has been reported that in intestinal inflammatory diseases, 
proinflammatory cytokines generate important alteration of epithelial barrier structure and 
functionality, leading to an increase in the permeability of substances via paracellular route to 
intestinal lumen [4]. From the present data, a long term treatment of Caco-2 cells with IL-4 
and IL-13 did not significantly affect transepithelial resistance. However, TNF-ĮVKRZHGDQ
opposite result; the significantly decreased TEER values of Caco-2 layers during 21 days of 
experiment. These results are reflected in the FD10 transport across treated epithelium. The 
long-term exposure to pro-inflammatory cytokines did not provide notable effect on the Papp 
values for IL-4 and IL-13, but showed a dramatic effect in the TNF-Į WUHDWPHQW ZLWK
approximately 14.5- and 77.5-fold increase for Caco-2 and Calu-3 layers. The general trend 
of increased permeability following TNF- ĮWUHDWPHQWZDVVHHQLQWZRVHSDrate experiments, 
although the absolute values are substantially different and potential future work would need 
to study more biological replicates. The future work would also need to consider a long term 
application of IL-4+IL-13 combination in CaCo-2 cells, as this has shown a significant effect 
in the short term experiment.  
With regard to Caco-2 cells, our results for IL-4 and IL-13 are in agreement with a study 
which reported that no significant effect was observed with recombinant IL-4 and IL-13 
treatment in vitro [26]. The possible explanation might be that the interleukins play a role in 
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protecting the functionality and structure of the epithelium during long-term treatment. This 
observation also agrees with previous studies which demonstrated that IL-4 and IL-13 have 
anti-inflammatory properties in such cell lines, e.g. H-29 [26]. In contrast, another published 
work demonstrated that recombinant IL-4 and IL-13 contributed significantly to the damage 
of Caco-2 epithelial monolayers [27]. Potentially dual anti-inflammatory and pro-
inflammatory action of IL-4 and IL-13 has been seen in several conditions [26], and this 
might be the most likely reason for different effect of IL-4 and IL-13 on epithelium in 
different cases. Taking this further, an intestinal study demonstrated that it could be a good 
strategy to use IL-4 and IL-13 to treat inflammatory intestinal conditions by inhibiting the 
effect of other pro-inflammatory cytokines [26]. Furthermore, both interleukins have the 
capacity to inhibit the production of pro-inflammatory cytokines in different inflammatory 
conditions [26].  
With regard to intestinal cell line models, TNF-ĮZDVVKRZQWRSURGXFHDVLJQLILFDQWHIIHFW
on epithelial barrier in HT29/B6 cell line, while in T84 cell model TNF-ĮLWGLGQRWSURGXFH
notable effects [4]. Another recent study documented that TNF-Į FDQ VWLPXODWH WKH Wight 
junction modification and produce chronic damage of in vitro epithelial layer models [28]. 
The effect of TNF-ĮRQLQWHVWLQDOFHOOVZDVQRWDVFULEHGWRDSRSWRVLVDFWLRQ[4], but the TNF-
Į FDSDFLW\ WR SURGXFH VLJQLILFDQW DOWHUDWLRQ LQ &DFR-2 epithelial barrier characteristics [29], 
which consequently increased the permeability. The dose of cytokines that were applied on 
epithelial cells may play a role in the intensity of its effect [26]. This has not been assessed in 
the present study, but the future potential work would need to consider such experiments. 
Moreover, the prolonged contact time with  cytokine would increase the probability of 
producing significant effect, as shown in the present study in the experiment that compare the 
influences of short-term and long-term TNF-Į 
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A study demonstrated that epithelial monolayers could release cytokines in inflammatory 
condition [30]. In asthma, proinflammatory cytokines that are released by epithelium can 
produce potent effects on remodelling of tight junction structure [31]. Inflammation reaction 
such as asthma could cause irreversible destruction in epithelial tissue [30]. In case of AIC 
Calu-3 treatment, different results were obtained from treating the cells with IL-4, IL-13 and 
TNF-a for 21 days. Our TEER and FD10 permeability data demonstrated that short exposure 
of the formed airway epithelial layer to the pro-inflammatory cytokines used in this study did 
not cause significant influence. Long-term / chronic treatment with TNF-a however provided 
a significant effect on Calu-3 permeability in one of the experiments conducted, and no 
significant effect in the other. The effect seen could be resulting from a prolonged interaction 
time between the recombinant cytokine and airway epithelial monolayers, however the 
experiment would need to be repeated to confirm this. In chapter 3 and 4, we verified the 
effects of tested cytokines following short-term exposure (not more than 4 days), as reported 
in a few studies discussed. There is however no available data from literatures on the 
influence of chronic treatment on intestinal and respiratory cell line models. 
In asthmatic tissue, IL-4 and IL-13 might produce significant structural modification in 
epithelium [30]. IL-4 and IL-13 play important function on impairment of Calu-3 epithelial 
cells and prolong residence time could induce changes in the expression of epithelial 
membrane proteins, such as occluding expression [27]. Concerning the effect of IL-13 on 
Calu-3, it was shown to downregulate some tight junction proteins and increase an influx of 
molecules across the epithelial layer [29]. Similar observation was noticed in asthma 
individuals [27]. Other possible mechanism for the influence of IL-4 and IL-13 on airway 
epithelium is a decrease of cell migration, which could delay wound healing process [27]. In 
our study however, TEER and FD10 permeability data show that long-term treatment with 
tested of IL-4 and IL-13 interleukins did not have negative effects but may potentially 
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generate protective effect on epithelium overtime. Our results are consistent with other 
observations about the protective properties of these cytokines [26]. Further investigations, 
particularly on epithelial membrane gene expression, would be important to prove this 
hypothesis (see Chapter 6).  
Tumour necrosis factor has been shown to have a significant harmful effect on several cells 
[32]. A number of investigations concluded that TNF-ĮSOD\VDQHVVHQWLDOIXQFWLRQLQDVWKPD
disorder [22]. TNF-Į SOD\ D NH\ UROH LQ LQGXFH WKH DVWKPD LQIODPPDWLRQ [33]. Elevated in 
TNF-ĮH[SUHVVLRQZDVREVHUved in analysis from asthmatic individual [17][20].   
 
5.5  Conclusions 
 
Using Caco-2 and Calu-3 cells the present study investigated the effect chronic exposure with 
different cytokines on epithelial cells properties. We demonstrated that long-term treatment 
with proinflammatory cytokine TNF-ĮKDVDQLPSRUWDQWHIIHFWRQ the cell layers. TNF-ĮKDV
exhibited significant effect on TEER and FD10 permeability. However, IL-4 and IL-13 did 
not produce significant effects on the same cell lines. In Calu-3, no significant effect was 
observed with these cytokines in TEER, as well as in transport of FD10. This observation 
might be due to suggested anti-inflammatory properties of IL-4 and IL-13.. It should be noted 
that no much work was published about the effect of these cytokines on Calu-3 and Caco-2 
epithelial monolayers, particularly during prolonged incubation [26]. Furthermore, the data 
suggest that it may be useful to start further work on gene expression analysis to examine the 
regulation properties of proinflammatory cytokines on epithelial cells protein components 
expression [30]. 
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Chapter 6 
 Effect of Cytokines on the Expression of Human Intestinal and Airway Epithelial 
Barrier Genes 
 
 
 
6.1  Introduction 
 
Inflammation is an immunological reaction stimulated usually by endogenous and exogenous 
mediators via different mechanisms [1]. Several components of epithelium have been shown 
to be involved in the inflammation process mechanism in a wide range of inflammatory 
disorders [2]. Shaoyong et al. stated that a number of epithelial membrane proteins could be 
significant constituent of inflammation progression in human [3]. 
Epidemiological studies reported that modification in the expression of epithelial barrier 
genes is one of the important factors  that might play a significant function in such intestinal 
inflammatory disorders [4][5][6]. In addition, in pulmonary inflammatory conditions, there is 
strong evidence that the development of asthma, for instance, is based mainly on changes in 
the expression of such airway barrier genes, which might drive medical research in future 
into new insight of therapy [7][8][9][10].  Most patients suffering from inflammatory 
diseases are dissatisfied with current anti-inflammatory treatment, while good understanding 
of the contribution of genes up- or down-regulation in the inflammation process could lead to 
discover a novel therapeutic strategy for clinical applications [6][11][12]. In addition, 
understanding of the expression features of epithelium in inflammation reaction will help 
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inventors to create well-characterised in vitro models of inflamed cells, and this will support 
researchers to examine the efficacy of new anti-inflammatory agents.  
Recently, numerous investigations have demonstrated that the remodelling of epithelial tight 
junction structure is considered a key feature of the pathophysiology of inflammatory disease, 
and the epithelial membrane proteins might play a central function in this alteration 
[13][14][15][16]. The literature reports different epithelial membrane genes as shown in 
Table 6.1 that may provide important functions in formation, regulation and transport 
processes across epithelial membranes. It can be hypothesised that these genes play vital roles 
in the modulation of tight junction complex structure and function in inflamed epithelial 
tissue.
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Gene Symbol 
 
Gene Name 
 
Function 
 
Reference 
TJP1 tight junction protein 1 
(zona occludens 1) 
Tight junction formation 
and  regulation 
[17] 
TJP2 tight junction protein 2 
(zona occludens 2) 
Tight junction formation 
and  regulation 
[18][19] 
TJP3 tight junction protein 3 
(zona occludens 3) 
Tight junction formation 
and  regulation 
[20][21] 
CDH1 cadherin 1, type 1, E-
cadherin (epithelial) 
Regulating cell-cell 
adhesions (adherence 
junctions protein) 
[22] 
CAV1 caveolin 1, caveolae 
protein 
Transport via endocytosis 
pathway 
[23] 
LAMP1 lysosomal-associated 
membrane protein 1 
Late endosome and 
lysosomes 
[24][25] 
CLTC clathrin, heavy chain (Hc) Regulation endocytosis 
pathway 
[26] 
CLDN1 claudin 1 Formation of tight junction [27] 
CLDN4 claudin 4 Formation of tight junction [28] 
CLDN5 claudin 5 Formation of tight junction [29] 
FCGRT Fc fragment of IgG, 
receptor, transporter, alpha 
Transfer of IgG from 
mother to fetus 
[30] 
CUBN cubilin (intrinsic factor-
cobalamin receptor) 
Endocytic receptor [31] 
FOLR1 folate receptor 1 (adult) Membrane-bound protein [32] 
EEA1 early endosome antigen 1 Endosome fusion [33] 
RAB4A RAB4A, member RAS 
oncogene family 
Cell adhesion and early 
endosome 
[34][35] 
RAB5A RAB5A, member RAS 
oncogene family 
Fusion of plasma 
membranes and early 
endosome 
[36][37] 
RAB7A RAB7A, member RAS 
oncogene family 
Late endocytic transport [38] 
RAB9A RAB9A, member RAS 
oncogene family 
Late endocytic transport [39] 
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RAB11A RAB11A, member RAS 
oncogene family 
Regulates endocytic 
recycling 
[40] 
M6PR mannose-6-phosphate 
receptor (cation 
dependent) 
Late endocytic transport [41] 
FPR1 formyl peptide receptor 1 Activation of neutrophils [42] 
OCLN occludin Formation and regulation 
of the tight junction 
[43] 
 
Table 6.1  Several genes whose expression features could play key roles in remodelling 
of the epithelium in inflammatory conditions. 
 
From the table above, the candidate genes would be analysed by using gene expression 
microarray data from the Gene Expression Omnibus (GEO) database to distinguish the 
difference of gene expression in normal and inflammatory condition and to select the genes 
of interest that are suitable to be investigated in this chapter. 
Gene Expression Omnibus (GEO) is a public microarray databank created in 2000 by the 
National Centre for Biotechnology Information (NCBI) to archive experimental information 
of mRNA, protein molecules and genomic DNA, which are used routinely in biomedical and 
molecular biology research [44][45][46][47]. Nowadays, numerous researchers mine the 
GEO database to identify candidate genes, to confirm their results and to design further 
studies [48].  
In 2006, GEO contained more than 20.000 studies, about 33 billion individual measurements 
and about half a million samples [49]. GEO database contains three types of data which are 
series, platform and sample [50]. Platform is the type of array used in the experiment and 
identified by (GPL) prefix [51]. Sample is the collection of a summary of the materials and 
general methodology used in the experiment and known by (GSM) prefix [52]. Finally, series 
is a collection of samples which composed  part of a study and is known by (GSE) prefix 
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[49]. Also, there is a further tool called Dataset which is known by (GDS) prefix, and 
contains complete summary of final values [53]. GEO database can be accessed freely on 
(GEO; http://www.ncbi.nlm.nih.gov/geo). 
 
In an attempt to investigate the contribution of specific genes involved in epithelial transport 
under conditions of increased inflammatory mediators in epithelial tissue, Caco-2 and Calu-3 
cell lines were used. Caco-2 monolayers are a well characterised cell line that represents an in 
vitro model of intestinal mucosa and is used widely among varieties of pharmaceutical 
research [55]. The Calu-3 cell line, originally derived from bronchial tissue, is used 
commonly as a model of the in vivo situation of airway epithelium in normal state [56][57]. 
 
The expression patterns of selected genes were examined in this chapter in three different 
conditions. First, epithelial cells treated with a proinflammatory cytokine (TNF-Į IRU 
days, mimicking a chronic inflammatory condition. Second condition, 4 days of treatment 
was used in Caco-2 and Calu-3 monolayers, mimicking an acute inflammatory condition. 
Finally, cells were cultured without cytokine treatment. We hypothesized that the gene 
expression of intestinal and airway epithelium would be similar to that of Caco-2 and Calu-3, 
respectively. It should be noted that proinflammatory cytokines play a central role in 
stimulating the inflammation process as host defence mechanism [58][59], as mentioned in 
detail in previous chapters.  
 
In general, it is still unclear how these genes contribute in the alteration of epithelial barrier 
structure and function in inflammatory disorders. Hence, this chapter seeks to define the 
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correlation between inflammatory state and gene expression using in vitro models of 
epithelial membrane treated with proinflammatory mediators. Good understanding of this 
correlation could help researchers in academia or the pharmaceutical industry to employ these 
systems as models of inflamed airway and intestinal epithelium. 
 
 
6.2  Methods 
 
6.2.1  Cell Culture and Cytokine Treatment 
 
Caco-2 Cells were originated from human colorectal adenocarcinoma and purchased from the 
European Collection of Cell Cultures (ECACC number; 86010202). Caco-2 cells were used 
LQ WKLV ZRUN ZLWK SDVVDJH QXPEHU  DQG FXOWXUHG XVLQJ 'XOEHFFR¶V 0RGLILHG (DJOHV
Medium (DMEM). Calu-3 cells were originated from human bronchial adenocarcinoma and 
obtained from the American Type Culture Collection (ATCC number; HTB-55). Calu-3 cells 
were used with passage number (36) and cultured using Eagle`s Minimum Essential Medium 
(EMEM). Both DMEM and EMEM were purchased from Sigma-Aldrich (UK). Caco-2 and 
Calu-3 cells were seeded with 100.000 cells/well seeding density in 12 mm diameter and 0.4 
ȝP SRUH VL]H SRO\VW\UHQH SHUPHDEOH LQVHUWV 7UDQVZHOO®) were supplied by Corning Life 
6FLHQFHV86$&HOOVZHUHLQFXEDWHGDWÛ&LQDKXPLGLILHGLQFXEDWRUZLWK&2 
Recombinant human proinflammatory cytokine TNF-Į ZDV SXUFKDVHG IURP 5	' 6\VWHPV
(UK) and mixed with master medium with (25ng/ml) concentration. Three conditions were 
created for each cell line: cells with TNF-Į IRU GD\V FHOOV ZLWK 71)-Į IRU  GD\V DQG
control (cells without TNF-ĮWUHDWPHQW)ROORZLQJWUHDWPHQWZLWK71)-Į&DFR-2 and Calu-
3 cells were lysed for gene expression analysis. More information about this study was 
explained minutely in Chapter 2.2.6. 
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6.2.2  Primer Design for PCR 
 
Primer design for the RT±PCR experiment was made by Primer-BLAST 
(www.ncbi.nlm.nih.gov/tools/primer-blast/). Primers were designed across an intron to 
discriminate cDNA from genomic DNA contaminants, and taking into account the existence 
of known splice variants. The specificity was checked using Primer- BLAST. Primers 
(desalted) were purchased from Sigma-AldULFK DQG GLVVROYHG LQ ZDWHU DV  ȝ0 VWRFN
solutions. All primers were analysed for optimal annealing temperature using a gradient 
cycler. In these experiments, the human housekeeping gene Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as control. The primers used in this study are as follows: 
Gene Forward primer Reverse primer Product size 
TJP2 v1 CAGGCATGGAAGAGCTGATA CCGGGAGCACATCAGAAAT 150 bp 
 
TJP2 v2 GGAGGATGTGCTTCATTCGT CGCATGGTCTTGGTCCAG 
 
352 bp 
TJP3 v1 GGGACCTGCCTCCCTGTTGC GGTCGCCTGTCTGTAGCCTGC 
 
342 bp 
 
TJP3 v2 GGGTGGGGGCCGATTGACTG 
 
GTCGCCTGTCTGTAGCCTGCC 
 
264 bp 
 
LAMP1 CACGCTGTGAACAAGACAGG TGTTGGGGTTGATGTTGAGA 219 bp 
 
RAB4A TGATATCACCAGCCGAGAAA GAGCAAATCTGGAGGCTTCT 158 bp 
 
RAB5A CTCGGCTTGCTGCGGTCTCA TGCCAACAGCGGACTCTCCCA 
 
211 bp 
 
 
Table 6.2 List of forward and reverse primers used to examine the expression features of 
candidate genes.  
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6.2.3  PCR Analysis 
 
Total mRNA was isolated and reverse transcribed into cDNA using the OneStep cDNA 
synthesis kit (Miltenyi Biotec) IROORZLQJ WKH PDQXIDFWXUHU¶V SURWRFRO (DFK 3&5 UHDFWLRQ
FRQWDLQHGȝORI-XPS6WDUW7DT'1$SRO\PHUDVHPL[6LJPD-$OGULFKȝORISULPHUV
ȝORIF'1$IRU VSHFLILF FRQGLWLRQDQG ȝO IUHH'1$DQG51$ZDWHUȝORI3&5
samples were mixed in PCR tubes. A 96-Well PCR Thermal Cyclers (Thermocyclers) was 
XVHGZLWKÛ&DQQHDOLQJWHPSHUDWXUHDQGF\FOHVRIKHDWLQJDQGFRROLQJ7KHÛ&ZDV
used as a suitable annealing temperature for all examined genes. 
The amplified products were confirmed by their expected sizes using 2% agarose gel 
electrophoresis run in 0.5x Tris-Borate-('7$7%(EXIIHU VWDLQHGZLWKȝJPOHWKLGLXP
bromide and imaged using SynGene Genius equipment and GeneSNAP imaging software. 
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6.3  Results 
 
6.3.1 Expression Analysis of Candidate Genes 
 
The list of candidate genes in Table 6.1 whose expression features could play a significant 
role in transport processes across the epithelial membrane were analysed by normalising the 
expression microarray data of each gene against appropriate housekeeping genes [54] in 
normal and inflammation state (asthma) and the results are shown in Table 6.3. 
 
Table 6.3  Summary of gene expression data analysis performed on the lung tissue of 
asthmatic and non-asthmatic individuals for a list of candidate genes and examined by GEO 
database (ns: not significant,    : downregulated,    : upregulated). Statistical analysis was 
calculated by t-test, P value (ns >  0.05, * <  0.05, ** <  0.001, *** <  0.0001). 
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Table 6.3 shows the result summary of analysed expression data of the candidate gene 
microarray in four different studies with different sample numbers. From the table, five 
different genes were selected to be further investigated in this chapter. These genes are TJP2, 
TJP3, LAMP1, RAB4A, and RAB5A. These genes show interesting expression data from 
primary data analysis and it would therefore be useful to confirm their enrolment in the 
inflammation reaction in more depth. TJP2 and TJP3 are main components of paracellular 
pathway of transport in epithelial membrane, while the rest of the genes are involved mainly 
in the endocytosis pathway. Studies stated that TJP2 and TJP3 are corner-stones in the 
formation of tight junction complex in epithelium [18][20]. In addition, LAMP1 and RAB5A 
contribute in late and early endosome process, respectively [24][36]. Furthermore, RAB4A is 
reported to play a role in cell-cell adhesion in epithelial tissue and is also involved in 
endocytosis pathway [34][35]. The figures below reported that these genes show significant 
difference in expression level in inflammatory condition (asthma) compared with healthy 
control confirmed by t-test of significance. 
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Figure 6.1 Graph shows significant 
difference between the expression of normal 
control (healthy individuals) and diseased 
condition (asthmatic patients) in TJP2 gene. 
Statistical analysis made by t-test of 
significance. P value (ns > 0.05, * < 0.05, ** 
<  0.001, *** < 0.0001) 
Chapter 6                                  Effect of Cytokines on the Expression of Human Intestinal and  
                                                  Airway Epithelial Barrier Genes 
130 
 
 
TJP3
R
M
A 
n
o
rm
al
iz
ed
 
in
te
n
si
ty
control asthma
5.0
5.5
6.0
6.5
7.0
7.5
8.0
P value 0.0295
 
LAMP1
R
M
A
 
n
o
rm
a
liz
e
d 
in
te
n
s
ity
control asthma
5.0
5.5
6.0
6.5
7.0
7.5
P value 0.0063
 
RAB4A
R
M
A
 
n
o
rm
a
liz
e
d 
in
te
n
s
ity
control asthma
6
7
8
9
10
P value 0.0002
 
Figure 6.2  Graph shows significant 
difference between the expression of 
normal control (healthy individuals) 
and diseased condition (asthmatic 
patients) in TJP3 gene. Statistical 
analysis made by t-test of significance. 
Figure 6.3  Graph shows 
significant difference between the 
expression of normal control (healthy 
individuals) and diseased condition 
(asthmatic patients) in LAMP1 gene. 
Statistical analysis made by t-test of 
significance. P value (ns >  0.05,  <  
Figure 6.4  Graph shows significant 
difference between the expression of 
normal control (healthy individuals) and 
diseased condition (asthmatic patients) 
in RAB4A gene. Statistical analysis 
made by t-test of significance. P value 
(ns >  0.05, * <  0.05, ** <  0.001, *** < 
0.0001) 
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These results led us to investigate the expression levels of these genes in inflammation using 
an in vitro model of cells exposed for prolonged period of time to the inflammatory 
mediators.  
 
6.3.2  Effect of TNF-ĮRQWKH([SUHVVLRQRI&DFR-2 and Calu-3 Barrier Genes 
 
Figure 6.6 shows the time dependent influence of recombinant human proinflammatory 
cytokine TNF-Į QJPORQ P51$H[SUHVVLRQ IHDWXUHVRISURWHLQFRPSRQHQWVRI&DFR-2 
and Calu-3 epithelial cell layers. The isolated mRNA was reverse transcribed into cDNA and 
examined by PCR analysis technique.  
 
In case of the first splice variant of TJP2 gene, Caco-2 cell line did not express this gene 
showing by comparison of Caco-2 expression with GAPDH control bands. However, TJP2 
Figure 6.5  Graph shows significant 
difference between the expression of 
normal control (healthy individuals) and 
diseased condition (asthmatic patients) in 
RAB5A gene. Statistical analysis made by 
t-test of significance. P value (ns >  0.05, * 
<  0.05, ** < 0.001, *** < 0.0001) 
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v1 shows interesting expression results on Calu-3 cells. TNF-ĮZDVREVHUYHGWRFDXVHGRZQ
regulation of this gene. The expression bands show TJP2 v1 expressed constitutively in Calu-
3 control, while Calu-3 cells treated with TNF-ĮVKRZNQRFNGRZQRI7-3YDQGWKLVHIIHFW
would increase with exposure time. The time course of the TNF-ĮLQGXFHGGHFUHDVHLQ7-3
v1 expression correlated with the time of treatment showing stronger down regulation effect 
on TJP2 v1 in 21 days than in 4 days of TNF-Į WUHDWPHQW :LWK UHVSHFW WR WKH H[SUHVVLRQ
features of the second splice variant of TJP2, Caco-2 and Calu-3 cell lines did not show 
changes in gene expression with TNF-ĮWUHDWPHQW%\FRPSDULQJ*$3'+EDQGVZLWK7-3
v2 bands, no significant effect was observed in mRNA expression. In addition, TNF-ĮGLGQRW
influence the TJP2 v2 expression correlated with increased time of treatment.  
 
In case of the first splice variant of TJP3 gene, no meaningful effect of TNF-Į WLPH-
dependent treatment was detected. This result confirmed that TNF-Į GRHV QRW SURYLGH
significant effect on mRNA expression of variant 1 of TJP3 showing by comparing the 
expression bands on Caco-2 and Calu-3 conditions with GAPDH. With regards to the second 
splice variant of TJP3, prolonged TNF-Į WUHDWPHQWDSSHDUHGWRFDXVHXS UHJXODWLRQ LQ ERWK
Caco-2 and Calu-3 cell lines. By comparing the control bands in both cells with the bands of 
treated cells, increased expression of TJP3 v2 was observed with TNF-Į WUHDWHG FHOOV 7KH
duration of the TNF-Į WUHDWPHQW GLG QRW DSSHDU WR DIIHFW 7-3 Y P51$ H[SUession as 
suggested by the similar levels with both incubation times (4 and 21 days).  
 
With regard to LAMP1, RAB4A and RAB5A genes expression, Caco-2 and Calu-3 cell lines 
constitutively expressed the mRNA for these genes in the presence or absence of the 
proinflammatory cytokine TNF-Į 7KHVH UHVXOWV VXJJHVW WKDW 71)-Į GRHV QRW KDYH D
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significant effect on the expression of these genes on epithelial barriers of intestinal and 
pulmonary tissues showing by comparing the obtained bands with the expression of control 
mRNA (GAPDH). 
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Figure 6.6  Effect of time-dependent proinflammatory cytokine TNF-ĮQJPOWUHDWPHQW
on mRNA expression of Caco-2 and Calu-3 epithelial membrane genes. The genes examined 
in this study were TJP2v1, TJP2v2, TJP3v1, TJP3v2, LAMP1, RAB4A, and RAB5A. Human 
GAPDH was used as a housekeeping gene (control). 
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6.4  Discussion 
 
In the past, numerous laboratories have attempted to design well-characterised in vitro 
models of inflamed epithelium in order to understand the basic mechanisms of such 
inflammatory reactions, to study the effect of diseased tissue on drug delivery properties and 
to examine anti-inflammatory action of such new therapeutics. At present, there are no 
available methods accepted to be a good in vitro model for inflammation. Caco-2 and Calu-3 
cell lines are used widely in research as an in vitro model of intestinal and airway epithelium, 
respectively. We hypothesised that treating these cell lines with proinflammatory cytokines 
under specific conditions would establish a good in vitro model of inflamed epithelium.  
In vivo, such TNF-Į PD\ EH UHOHDVHG E\ ORFDO UHVLGHQWPDVWFHOOV LQFORVHSUR[LPLW\RI WKH
epithelium, which may also be increased during chronic inflammation.  
The results in previous chapters 3, 4, and 5, indicate that the treatment of Caco-2 and Calu-3 
with proinflammatory cytokines could result (although experiments would need to be 
repeated) in significant effect on TEER profiles of cells and on tight junction formation, 
particularly with TNF-Į 
In this chapter, the work aimed to investigate the expression features of such epithelial 
membrane genes (TJP2, TJP3, LAMP1, RAB4A, and RAB5A) which could play an essential 
function in regulation of mucosal barriers using PCR. Results will provide a primary 
overview of gene expression features and would allow drawing of an initial assumption about 
the capacity of these cells to be appropriate models of inflammation. These genes are 
expressed widely in cultured cells, and TJP2 and TJP3 are known to be components of tight 
junctions and are used as indicators of tight junction formation and epithelial membrane 
integrity, whilst the rest of the genes are usually involved in endocytosis pathway. In this 
work, samples were obtained for RT-PCR at day 21 and cells were examined at the same 
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time of culture and taken from the same batch of cells to decrease the variation in 
experiments. 
 
Tight junction proteins TJP2 and TJP3 (a.k.a. ZO-2 and ZO-3) are important components in 
regulation and formation of tight junction and control the transport across epithelial barrier 
via paracellular pathway [60][61]. Under normal (i.e. non-inflammatory) conditions, TJP2 
and TJP3 are expressed normally in both Caco-2 and Calu-3 cells [62][63] and help to 
prevent harmful substances from  entering the tissues from the host lumen of intestine and 
lung, while in inflammatory conditions, tight junctions might be characterised by increased 
permeability via the paracellular route [64].  
From our results, we found that TJP2 showed time-dependent down regulation in Calu-3 
cells, where TNF-Į VWLPXODWHG WKH XS UHJXODWLRQ RI 7-3 LQ ERWK &DFR-2 and Calu-3 cells. 
These results suggest that tight junction complex may be an attractive target for anti-
inflammatory mediators in the in vivo system. In addition, TJP2 might be involved in the 
regulation of epithelial barriers in the in vitro model of airway, while TJP3 could be involved 
in the intestinal model as well. The significance of the different splice variants of TJP2 and 
TJP3, and of their differential regulation by TNF-ĮLVFXUUHQWO\XQFOHDU 
 In inflammatory disorders, one important issue is the increased permeability of noxious 
elements across epithelial layer due to disruption of the tight junction barrier [55]. Numerous 
studies have reported that inflammatory diseases occur perhaps due to disruption of the 
epithelial membrane and changing the expression of tight junction proteins might play an 
important role in this defect [62]. We can suggest that tight junctions were involved 
importantly in inflammation reaction on epithelial membranes. 
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Time-course is indeed responsible for the TNF-Į IDFLOLWDWHG VWLPXODWLRQ RI 7-3 Y
expression in Calu-3 monolayers. We observed in chapter 5 that TNF-ĮLQFUHDVHSHUPHDELOLW\
of epithelial membrane with increase in the time of treatment. Taken together, it could be 
established that TNF-Į SOD\V D UROH LQ G\VIXQFWLRQ RI WLJKW MXQFWLRQ SRVVLEO\ E\ GRZQ
regulation TJP2; this effect would be increased with prolonged exposure to TNF-Į+RZHYHU
the differences in expression of tight junction proteins variants remain unclear. In the 
literature, nothing is mentioned about the expression of different variants of tight junction 
proteins. 
 
On the other hand, several studies demonstrated that LAMP1, RAB4A and RAB5A 
contribute in transport elements across epithelium via endocytosis pathway [25][34][36]. 
Study reported that LAMP1 plays multiple functions in transport across the cell membrane 
via endocytosis [65]. RAB4A and RAB5A are important members of the RAB family and 
they have a role in regulation of early and recycling endosomes process, respectively and also 
endocytosis pathway of transport in a wide range of cells [35][66][67][68]. LAMP1, RAB4A, 
and RAB5A did not show alteration in expression during treatment of the cells with 
proinflammatory cytokines. By combining the previous results of tight junction proteins with 
these results, it can be suggested that the increased permeability observed during 
inflammation could be mediated due to disruption of tight junction complex resulting in 
increased transport across epithelial membranes through paracellular pathway rather than 
through the endocytosis route. To the best of our knowledge, we have not been able to find 
any information regarding expression features of these genes in inflammatory conditions in 
the literature. 
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6.5  Conclusion 
 
The data in this chapter show that treatment of the cells with cytokines did not produce a 
significant effect on the expression array of the protein components of endocytosis 
membrane. It would be concluded that tight junctions might be involved in the epithelial 
barriers modifications more than endocytosis pathway during inflammation reaction. In vivo 
or ex vivo (e.g. using biopsies from patients) studies should be established to confirm these 
results, to find out if pre-treated cell lines mimic the in vivo situation or not. Furthermore, 
additional investigations should be focused in the direction of critical problems addressing 
the fundamental character of inflammation, the functional importance of intestinal and airway 
remodelling, and the role of gene expression in disease states. 
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7.1  Overall Summary 
 
Mucosal barriers have a protective role by acting as a permeability barrier limiting the 
movement of undesirable materials from the external environment into the systemic 
circulation. However, it has been realized the barrier properties of mucosal epithelium can be 
significantly altered in inflammation conditions, in terms of its function and structure. 
Alterations in the tight junction complex have been reported to occur in inflammatory 
disorders affecting the epithelium. As a result, the mucosal barriers in inflammatory 
conditions have increased the paracellular permeability. The changes in epithelium, including 
the tight junctions, have been attributed to up-regulation of proinflammatory cytokines. 
 
To investigate the effect of pro-inflammatory cytokines on permeability function of mucosal 
membrane in vitro, we need a cell line model of the tissues of interest. The cell line models 
provide several benefits in comparing with primary cells and animal models as they are cost-
effect, easier to maintain and show higher in reproducibility. In this work, Calu-3 and Caco-2 
cell lines were used to represent the airway and intestinal epithelium, respectively. Both these 
cell lines are capable of producing polarised layers when cultured appropriately. Another 
benefit of using Calu-3 cells is their ability to produce mucus when cultured adequately. The 
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Caco-2 cell line has a capacity to mimic the in vivo situation of intestinal epithelium more 
closely than other cell lines. Chapter 1 in this thesis discussed these cell lines in more details.  
 
The effect of proinflammatory cytokines on the epithelial barrier of the cell monolayers 
(Calu-3 and Caco-2) was investigated by treating the cells with cytokines and assessing the 
barrier function. IL-4, IL-13, and TNF-ĮZHUHWHVWHGLQWKLVZRUNDQGWKHEDUULHUIXQFWLRQZDV
assessed by measuring TEER, permeability and structural changes in the tight junctions. 
 
Chapter 3 assessed the effect of the tested cytokines on the barrier characteristic of Calu-3 
cell layers. The data demonstrated that TNF-Į LV WKHPRVWHIIHFWLYHF\WRNLQH LQDOWHULQJWKH
barrier function of Calu-3 cell layers, as shown by a significant decrease in TEER and 
increase in FD10 permeability. On the other hand, IL-4 and IL-13 failed to significantly 
influence the TEER and permeability. Applying these cytokines in combination produced a 
synergetic effect, when TNF-ĮZDVSUHVHQWLQWKHFRPELQDWLRQ7KHWHVWHGF\WRNLQHVVHHPHG 
to influence the distribution of a tight junction protein, ZO-1, suggesting that alteration in 
epithelial barrier results from a tight junction effect. 
 
The influence of cytokines on the intestinal epithelium, using Caco-2 cells as a model, was 
assessed in chapter 4. The data were less clear in this instance, with some evidence that TNF-
Į DQG ,/-4 produce some effects on the barrier when applied alone. When applied in 
combination all the tested cytokines markedly decreased cell layer TEER, though they failed 
to significantly increase FD10 permeability, except with IL-4/IL-13 combination. The data 
from Chapters 3 and 4 suggested that proinflammatory cytokines could increase the 
membrane permeability of airway and intestinal epithelium via the remodelling action on 
mucosal barriers. 
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While both chapter 3 and 4 aimed to establish the effect of short-term exposure of the cells 
with proinflammatory cytokines on the epithelial barrier, in chapter 5 the work explored the 
influence of long-term treatment of the cells with the same cytokines. Long-term treatment 
lasted for the whole duration of cell growth on filter supports. TNF-Į ORQJ-term treatment 
showed significant effect on Caco-2 cells, but no significant effect was observed with IL-4 or 
IL-13. 
 
Data shown in CKDSWHUDLPHGWRH[DPLQH LI WKHH[SUHVVLRQRIHSLWKHOLDOFHOO µPDUNHUV¶RI
interest if affected during inflammation reaction, mimicked by the TNF-ĮDSSOLFDWLRQ,QWKLV
experiment, Calu-3 and Caco-2 cells were incubated with TNF-Į IRU VKRUW DQG ORQJ WLPH
period (4 and 21 days, respectively). The PCR results demonstrated that down-regulation of 
TJP2 and up-regulation of TJP3 might play important role in paracellular tight junction 
remodelling in inflammatory disorders. Conversely, LAMP1, RAB4A, and RAB5A did not 
show difference in expression during the experiment, suggesting no involvement in epithelial 
modification. 
 
In conclusion, this work confirmed the previous reports that proinflammatory cytokines, the 
expression of which is up-regulated in inflammatory conditions affecting the epithelium (e.g. 
DVWKPDDQG&URKQ¶VGLVHDVHDOWHUWKHHSLWKHOLDOEDUULHU7KLVDOWHUDWLRQLVOLNHO\WRUHVXOWIURP
an effect on the tight junctions, as shown by changes in the appearance and the level of 
expression of these proteins following epithelial cell treatment with the cytokines. The 
GHIHFWLYHPXFRVDOEDUULHU LQLQIODPPDWRU\FRQGLWLRQVVXFKDVDVWKPDRU&URKQ¶VGLVHDVHFDQ
potentially be exploited for mucosal delivery of biotherapeutics. 
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7.2  Future Work 
 
Whilst this work showed the epithelial barrier-disruptive effects of three tested cytokines, it 
would be interesting to identify precisely the conditions of the epithelium in different 
inflammatory diseases. Specifically, the levels of other pro-inflammatory (as well as anti-
inflammatory) cytokines are likely to be altered (upregulated or downregulated) under 
inflammatory conditions. Establishing the effect of these precise conditions on the barrier 
property of the epithelium would give a more accurate indication of how the epithelium is 
affected in inflammatory diseases of the epithelium.  
This work has also implications in research related to establishing suitable models of 
inflamed epithelial tissue to study the disease itself, as well as drug delivery in these 
conditions. This is important as the use of standard models (e.g. cell line based models or 
excised tissue) to predict drug absorption in inflammatory epithelial conditions is not 
appropriate. Models based on culture of epithelial cell lines with proinflammatory cytokines 
may provide appropriate models, though these models need to be validated extensively in 
terms of their similarity (e.g. protein expression and permeability) to the inflamed mucosal 
tissue in vivo.  
Applying proinflammatory cytokines to the current in vitro models of epithelium, either lung 
or intestinal, under specific conditions could potentially create an in vitro model of inflamed 
epithelial tissue which could find its application in academia or pharmaceutical industry. 
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Chapter 8 
Appendices 
 
 
 
8.1  The Effect of TNF-ĮRQ&DOX-3 Cell Layers at Concentrations of (10, 25, and 
50ng/ml)  
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Figure 8.1  Effect of 10, 25, and 50ng/ml of TNF-ĮRQ7((5RI&DOX-3 layer. 
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8.2  Affymetrix Array of Candidate Genes from (GeneCards) 
 
 
 
 
 
 
Formyl peptide receptor 1 (FPR1) 
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Tight junction protein 1 (TJP1) 
 
 
 
 
 
Tight junction protein 2 (TJP2) 
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Tight junction protein 3 (TJP3) 
 
 
 
Caveolin 1 (CAV1) 
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Clathrin (CLTC) 
 
 
 
 
 
 
 
 
 
Claudin 5 (VCFS) 
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Claudin 4 (CLDN4) 
 
 
 
 
 
 
 
 
Cubilin (CUBN) 
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Early endosome antigen 1 (EEA1) 
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Lysosomal-associated membrane protein 1 (LAMP1) 
 
 
 
 
 
 
Cadherin 1 (CDH1)  
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Tight junction protein occludin (OCLN) 
 
 
 
 
 
 
Claudin1 (CLDN1) 
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Fc fragment of IgG receptor transporter alpha1 (FCGRT) 
 
 
 
 
 
 
Folate receptor 1 (FOLR1)  
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Member RAS oncogene family (RAB4A) 
 
 
 
 
 
Member RAS oncogene family (RAB5A) 
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Member RAS oncogene family (RAB7A) 
 
 
 
Member RAS oncogene family (RAB9A) 
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Member RAS oncogene family (RAB11A) 
 
 
 
 
Mannose-6-phosphate receptor (M6PR) 
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8.3  Normalizing Gene expression Data from (GEO) 
 
8.3.1  Study 1 
Series: GSE470, Platform: GPL8300, Sample number: 12 (6 healthy, 6 asthmatic). 
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8.3.2  Study 2 
Series: GSE18965, Platform: GPL96, Sample number: 16 (8 healthy, 8 asthmatic). 
 
 
 
 
 
Chapter 8                                                                                                             Appendices 
166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8                                                                                                             Appendices 
167 
 
 
8.3.3  Study 3 
Series: GSE4302, Platform: GPL570, Sample number: 26 (13 healthy, 13 asthmatic). 
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8.2.4  Study 4 
Series: GSE3212, Platform: GPL80, Sample number: 30 (15 healthy, 15 asthmatic). 
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